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SUMMARY 
International Nonproprietary Name (INN) prescribing is defined as using the INN for prescribing. It was 
introduced as an alternative way of prescribing to contribute to rational drug utilization. It has a legal foundation 
in many European countries, next to brand name prescribing, generic prescribing and generic substitution. INN 
prescribing is implemented and operationalized in various ways and to different extent within Europe. Since the 
global financial crisis also affected Europe, it was turned into a cost-containment measure in many European 
countries, also in Belgium, similar to generic substitution. However, when these two popular cost-containment 
measures are not rationally operationalized, it can result in dispensing errors, patient confusion, medication non-
adherence, and errors in self-administration. These consequences can abolish the savings made through INN 
prescribing and generic substitution.  
In Chapter 1, we presented how the implementation of INN prescribing in electronic prescribing in Belgium was 
prepared. During the project, which lasted almost six years, detailed operational rules were established, along 
with a classification of the Belgian therapeutic arsenal according to these operational rules. This project also 
showed that involving all stakeholders is a crucial item of success.  
In Chapter 2, the attitudes and opinions of Flemish general practitioners (GPs) and pharmacists towards INN 
prescribing were presented. Forcing INN prescribing into a cost-containment measure in spring 2012 in Belgium, 
resulted in negative reactions among primary health care professionals. The results of our questionnaire study 
showed that GPs and pharmacists prioritize patient safety and therefore they stressed the importance of 
continuity of treatment.  
In Chapter 3, the attitudes of medicine students and pharmacy students towards INN prescribing were 
presented. The students confirmed the opinions of their peers and indicated that more prominently teaching 
INN prescribing can stimulate the use of it in daily practice.  
Chapter 4 started with an overview of how INN prescribing and generic substitution are regulated and 
implemented in 16 European countries. The second goal of this study was to address the differences in (groups 
of) products exempted from INN prescribing and/or generic substitution. Part of these differences can be 
explained by the lack of a European definition and exhaustive list of narrow therapeutic index drugs. This study 
confirmed the need for a structured European guideline on these topics to harmonize the important differences 
in national regulation.  
Chapter 5 presented the results of our clinical trial with 800 mg gabapentin tablets. The antiepileptic drug 
gabapentin is frequently exempted from INN prescribing and/or generic substitution for patient safety reasons. 
This study confirmed bioequivalence between the brand and generic product with 800 mg gabapentin, also on 
the individual level. In addition, no differences between different batches of each product could be detected. 
These results indicated that switching between these products should be possible in clinical practice without 
affecting patient safety, provided correct medication use and adherence.   
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SAMENVATTING 
Voorschrijven Op Stofnaam (VOS) wordt in het algemeen gedefinieerd als het gebruik van de stofnaam om 
geneesmiddelen voor te schrijven. Internationaal wordt naar de stofnaam verwezen als de ‘International 
nonproprietary Name’, de ‘INN’ en wordt Voorschrijven Op Stofnaam ‘INN prescribing’ genoemd. Voorschrijven 
Op Stofnaam werd geïntroduceerd als een alternatieve manier van voorschrijven om bij te dragen tot rationeel 
geneesmiddelengebruik. VOS is, naast voorschrijven op merknaam, generisch voorschrijven en generische 
substitutie, in vele Europese landen wettelijk toegelaten. Echter, de manier waarop en de mate waarin VOS 
geïmplementeerd en geoperationaliseerd is verschilt sterk binnen Europa. Sinds 2008 werd VOS samen met 
generische substitutie in verschillende Europese landen gekoppeld aan besparingsmaatregelen. Alhoewel deze 
twee concepten kunnen bijdragen tot besparingen, moeten ze op een weldoordachte manier worden ingevoerd, 
om fouten in het geneesmiddelengebruik, verwarring bij patiënten en therapie-ontrouw te vermijden en er voor 
te zorgen dat de beoogde besparingen niet teniet worden gedaan door extra uitgaven.  
In Hoofdstuk 1 werd beschreven op welke manier in België de implementatie van VOS in elektronisch 
voorschrijven werd voorbereid. Tijdens dit project, dat meer dan vijf jaar duurde, werden er gedetailleerde 
operationele regels opgesteld en het Belgisch therapeutisch arsenaal werd volgens deze operationele regels 
ingedeeld. Dit project heeft ook aangetoond dat het vooraf consulteren van alle betrokken partijen een cruciale 
stap is om tot een succesvol einde te komen.  
In Hoofdstuk 2 werden de meningen van Vlaamse huisartsen en apothekers over VOS beschreven. De introductie 
van VOS als besparingsmaatregel in het voorjaar van 2012 ging gepaard met veel verontwaardiging en 
ongerustheid bij huisartsen en apothekers. De resultaten van de enquête tonen aan dat huisartsen en apothekers 
het belang en de veiligheid van hun patiënten voorop stellen en dat continuïteit van de behandeling hierin een 
sleutelrol speelt.  
In Hoofdstuk 3 bevestigden Vlaamse studenten geneeskunde en farmacie de mening van hun collega’s uit 
hoofdstuk 2. De studenten gaven ook aan dat als VOS meer aandacht zou krijgen tijdens de opleiding, dit de 
populariteit van VOS kan vergroten.  
Hoofdstuk 4 bevat een overzicht van de reglementeringen en implementatie van VOS in 16 Europese landen. 
Hier werden ook de verschillen tussen deze landen betreffende de (groepen van) geneesmiddelen die voor VOS 
en/of generische substitutie niet geschikt worden geacht besproken. Deze verschillen kunnen deels verklaard 
worden doordat er in Europa geen officiële definitie en exhaustieve lijst van geneesmiddelen met nauwe 
therapeutisch-toxische marge bestaat. De resultaten van dit hoofdstuk tonen ook aan dat er nood is aan een 
Europese regelgeving inzake VOS en generische substitutie.  
In Hoofdstuk 5 werden de resultaten van de klinische studie met gabapentine 800 mg tabletten weergegeven. 
Gabapentine is een antiepilepticum dat, omwille van patiëntveiligheid, vaak wordt aangeduid als een 
geneesmiddel waarbij frequent wisselen (‘switchen’) tussen de verschillende beschikbare merken wordt 
 9 
 
afgeraden. In dit onderzoek werd individuele bio-equivalentie aangetoond tussen het originele merkproduct en 
het generisch product van gabapentine. Eveneens konden geen verschillen worden aangetoond wanneer er 
meerdere lotnummers van elk product werden gebruikt. Dit onderzoek toont aan dat switchen tussen deze 
producten in de praktijk mogelijk is, zonder dat de patiëntveiligheid in het gedrang komt, op voorwaarde dat 
deze producten correct worden gebruikt.   
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ACRONYMS & SYMBOLS 
ABE Average Bioequivalence 
ACE Angiotensin-Converting Enzyme  
ADR Adverse Drug Reaction 
AE Adverse Event 
AED Antiepileptic Drug 
AUC0-inf Area under the plasma concentration-time curve from time zero to infinity 
AUC0-t Area under the plasma concentration-time curve from time zero to time t 
BA Bioavailability 
BCFI/ 
CBIP 
Belgisch Centrum voor Farmacotherapeutische Informatie/ 
Centre Belge d’Information Pharmacothérapeutique 
BE Bioequivalence 
CDER Centre for Drug Evaluation and Research 
CDOE Computerized Drug Order Entry 
Cmax Maximum (peak) plasma drug concentration 
dm+d Dictionary of Medicines + Devices 
ECG Electrocardiography 
EMA European Medicines Agency 
ERMS FG European Risk Management Strategy Facilitation Group 
EU European Union 
EudraCT European Clinical Trial database 
FAGG/ 
AFMPS/ 
FAMHP 
Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten 
Agence Fédérale des Médicaments et des Produits de Santé 
Federal Agency for Medicines and Health Products 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
GP General practitioner 
HMA Heads of Medicines Agencies 
IBE Individual Bioequivalence 
ICF Informed Consent Form 
ICH International Conference of Harmonization 
IMP Individual Medication Packaging 
INN International Nonproprietary Name 
NHS National Health Service 
NTI Narrow Therapeutic Index 
NTID Narrow Therapeutic Index Drug 
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PD Pharmacodynamic 
PIL Patient Information Leaflet 
PK Pharmacokinetic 
PPI Proton Pump Inhibitor 
PRN Pro Re Nata 
PSUR Periodic Safety Update Report 
R1 Reference 1 = Neurontin® 800 mg batch ‘A’ 
R2 Reference 2 = Neurontin® 800 mg batch ‘B’ 
RIZIV/ 
INAMI 
RijksInstituut voor Ziekte- en InvaliditeitsVerzekering/ 
Institut National d’Assurance Maladie-Invalidité 
sABE Scaled Average Bioequivalence 
SAE Serious Adverse Event 
SD Standard deviation 
SPC Summary of Product Characteristics 
SPSS Statistical Package for the Social Sciences 
T1 Test 1 = Gabasandoz® 800 mg batch ‘A’ 
T2 Test 2 = Gabasandoz® 800 mg batch ‘B’ 
T1/2 Elimination half-life 
TIAFT The International Association of Forensic Toxicologists 
Tmax Time to reach maximum (peak) plasma concentration following drug administration 
UCB Upper Confidence Bound 
UPLC-MS-MS Ultra Performance Liquid Chromatography – tandem Mass Spectrometry  
WHO World Health Organization 
WIPO World Intellectual Property Organization 
εI Sum of the maximum allowed estimate of the subject-by-formulation interaction 
η Function of different variance terms to establish individual bioequivalence 
θA The average bioequivalence limit, i.e. ln (1.25) = 0.223 
θI The individual bioequivalence limit, i.e. 2.5 
μR 
Population average response of the log transformed measure (AUC or Cmax) for the 
reference product 
μT 
Population average response of the log transformed measure (AUC or Cmax) for the 
test product 
σbatch Between-batch variability 
σD Subject-by-formulation interaction variability 
σW0 The specified constant within-subject variability 
σWR Within-subject variability for the reference product 
σWT Within-subject variability for the test product 
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OVERVIEW 
With this thesis, we will assess the regulation of International Nonproprietary Name (INN) prescribing in Belgium 
and Europe. INN prescribing is a concept and way of prescribing, introduced to contribute to rational drug 
prescribing and utilization. Despite the fact that is has a legal foundation in many European countries, it never 
really found foothold in continental Europe. That was until 2008, when the global financial crisis also affected 
Europe. From then, INN prescribing (and its related concept of generic substitution) was turned from an 
alternative, rational way of prescribing into a cost-containment measure. 
The general introduction of this thesis starts with a background on prescribing regulation and defines the 
different types of medicinal products and different types of medicines prescribing. It also provides an insight in 
the general concept of INN prescribing and its regulation in Belgium and Europe. 
The body of the thesis comprises five chapters, in which the results of the different studies, in line with the aims 
of this research, are presented. 
Finally, in the general discussion, all results are integrated and different points of attention for further 
improvement of the concept of INN prescribing are addressed. 
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1. PRESCRIBING REGULATION 
Within the European Union (EU) a medicinal product (syn. medicines, drugs) is defined as single or combined 
substances for prevention or treatment of diseases, or for making a medical diagnosis or to restore, correct or 
modify physiological functions by exerting pharmacological, immunological or metabolic action in humans [1].  
Medicines have been used since ancient civilization with “Mithridatium” (120 BC), an antidote for poisoning, as 
one of the first examples of a named drug with a fixed combination of ingredients. The first example of medicines 
regulation is perhaps the supervision of the manufacturing of Mithridatium and other medicines in 1540 in 
England [2,3]. The basis for modern medicines regulation was established in the 19th century with the evolution 
of life sciences, including chemistry, physiology and pharmacology. Since then, different aspects of medicines 
regulation were further elaborated and established after disasters involving medicines (e.g. diethylene glycol 
poisoning in 1930, anaplastic anemia as adverse drug reaction (ADR) of chloramphenicol around 1950 and the 
unknown teratogenic properties of thalidomide in the early 60ies) [2,4–6].  
Modern medicines regulation aims to promote and protect public health [2]. National medicines regulation 
differs in scope and implementation, as its characteristics are influenced by underlying attitudes of governments 
towards providing and financing healthcare and by their response to medical and financial crises [2,7].  
Medicines regulation covers different pharmaceutical policies, such as policies on registration, pricing, 
reimbursement and medicines prescribing. Medicines prescribing policy, also referred to as ‘prescribing 
regulation’, describes the applicable rules and practical implementation of the allowed ways of prescribing. The 
allowed ways of prescribing can be “brand name prescribing”, “generic prescribing” and “International 
Nonproprietary Name (INN) prescribing”. The allowed ways of prescribing are influenced by the available types 
of medicinal products in each country, which can be classified as “brand products” or “generic products”.  
Brand products include innovator products, licensed products and ‘well-established use’ products. All brand 
products have an invented name, i.e. the brand name, but differ in the type of submitted marketing authorization 
file. Innovators have to submit a complete marketing authorization file, containing results of pharmaceutical 
quality tests, pre-clinical tests (toxicological and pharmacological) and clinical trials [1,8]. Marketing 
authorization for licensed products and ‘well-established use’ products can be granted based upon an abridged 
file, without results of (pre-)clinical tests. These products are commonly referred to as ‘copies’. We prefer not to 
use this term as it comprises a container concept used to describe these two different types of medicinal 
products. Licensed products are products marketed by another company than the innovator company before 
patent expiry. The marketing authorization from the innovator company is then bought or duplicated for 
commercial reasons. The exact copy of the marketing authorization license is then referred to as a ‘piggy-back’ 
license [1,9].  ‘Well-established use’ products are products marketed based on a bibliographic file. Efficacy and 
safety of the active ingredient(s) can be demonstrated with scientific literature and they have to be used within 
the European Union for at least ten years [1].  
General Introduction 
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In the EU, a generic product is defined as a medicinal product with the same qualitative and quantitative 
composition in active ingredient(s) and the same pharmaceutical form as its reference product (usually an 
innovator product), and for which bioequivalence with the reference product is established, using the 
appropriate bioequivalence studies [1]. Products can serve as reference products if their patent has expired and 
if these are marketed for at least ten years in the EU. Generic products are marketed with an abridged 
authorization file containing results of the pharmaceutical quality tests and the appropriate bioequivalence 
studies, and references to the results of pre-clinical and clinical tests of the reference product [1,8]. As there are 
fewer research and development costs for generic products, these are cheaper than brand products [10].  
Generic products include ‘branded generics’ and ‘unbranded generics’. Both types of generics are marketed upon 
the same type of marketing authorization file, but differ in the way these are named. Branded generics can be 
named in two ways. Similar to brand products, the name of a branded generic  can be (1) an invented name (e.g. 
Lipcut®, which is the Sandoz® generic of simvastatin, available in Finland) or it can be (2) the active ingredient 
name (the INN) accompanied by the marketing authorization holder’s name (e.g. Simvastatin Sandoz®). The 
name of unbranded generics only includes the active ingredient name (the INN) on the product package, e.g. 
simvastatin.   
Possible ways to prescribe all these types of medicinal products are “brand name prescribing”, “generic 
prescribing” and “INN prescribing”. These ways of prescribing do not only differ in how medicines are prescribed, 
but also in the type of medicinal product that can be dispensed. Brand name prescribing refers to using the 
brand name for prescribing and having a brand product (innovator, licensed product or ‘well-established use’ 
product) dispensed. Generic prescribing covers the prescribing of a branded generic (referred to as branded 
generic name prescribing) and INN prescribing, provided this results in the dispensing of a generic product. INN 
prescribing involves the identification of the intended medicinal product by its active ingredient, and usually 
results in the dispensing of a generic product. It can however also result in the dispensing of a brand product, 
when the brand product has the same price as its generic counterpart or when there are no generic products 
available (yet).  
Closely related to INN prescribing is generic substitution. In contrast to INN prescribing, generic substitution is a 
pharmaceutical policy performed at dispensing level. It was introduced to enhance the role of the pharmacist 
and to promote the use of generic products. Generic substitution refers to substituting the prescribed medicinal 
product (a brand or generic product) at the pharmacy by another medicinal product (usually a cheaper one) 
which is equivalent to the prescribed one [11]. Generic substitution can occur with or without informing and 
permission of the prescriber and patient. For practical and patient safety reasons, many European countries have 
determined (groups of) medicinal products or specific situations where generic substitution is not advised or not 
allowed. These ‘exemptions’ differ widely between European countries. Generic substitution is not allowed in 
Belgium.  
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2. INTERNATIONAL NONPROPRIETARY NAME (INN) PRESCRIBING 
2.1. INTERNATIONAL NONPROPRIETARY NAMES  
The International Nonproprietary Names (INNs) constitute an international nomenclature to identify active 
ingredients of medicinal products. Each INN is internationally recognized, unique and public property. The 
nomenclature was initiated in 1950 and is operated since 1953 after publishing the first list of INNs [12]. The 
INNs are mandated by the World Health Organization (WHO), in collaboration with the World Intellectual 
Property Organization (WIPO) [12–14]. Currently, there are about 7000 INNs registered [12].  
Since the beginning, the aim was to contribute to the identification of medicinal products and to rational and 
safe medicines prescribing and dispensing, by providing a nomenclature with unique and universally available 
names for active ingredients. Additionally, using INNs can facilitate communication and information exchange 
(e.g. pharmacovigilance data) between scientists and health professionals [12].  
All INNs are designed to avoid confusion (with brand names) by using distinctive sound and spelling. The common 
suffix (called ‘stem’ by the WHO) provide an additional advantage to the nomenclature as it indicates the 
connection between pharmacologically related active ingredients (e.g. all INNs for Angiotensin-Converting 
Enzyme (ACE) inhibitors have ‘-pril’ as common suffix) (Figure 1) [12].  
Figure 1. All International Nonproprietary Names (INNs) for  
Angiotensin-Converting Enzyme (ACE) inhibitors,  
with their common suffix ‘-pril’ 
  
Angiotensin-Converting Enzyme (ACE) inhibitors
captopril
enalapril
lisinopril
perindopril
ramipril
quinapril
benazepril
cilazapril
fosinopril
trandolapril
spirapril
delapril
moexipril
temocapril
zofenopril
imidapril
General Introduction 
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2.2. INN PRESCRIBING 
Using the INN for prescribing, i.e. INN prescribing, was introduced in the mid-eighties in France, by ‘La Revue 
Prescrire’, an independent journal on treatment and health strategies [15]. The main purpose was to contribute 
to rational and safe medicines prescribing and utilization, by adding the advantages of the INN nomenclature to 
the prescribing process. Although endorsed by the WHO, INN prescribing was only slowly accepted as a way of 
prescribing in continental Europe, next to brand name and branded generic name prescribing [12,16]. 
2.3. INN PRESCRIBING IN EUROPE 
Twenty-six European countries provide a legal foundation for INN prescribing [17–20]. Since the global financial 
crisis also affected Europe, INN prescribing was one of the generic promotion measures, next to generic 
substitution and public awareness campaigns, implemented or elaborated to reduce pharmaceutical 
expenditures in many European countries [18]. The way and extent that INN prescribing is regulated and 
implemented varies widely between European countries. 
Since June 2014, it is mandatory to prescribe by INN for prescriptions which will be dispensed in another country 
within the EU. The aim is to facilitate patient mobility within the EU [21,22]. 
Similar to generic substitution, the regulation of INN prescribing describes (groups of) medicinal products or 
specific situations where INN prescribing might not be appropriate, for patient safety and practical reasons. 
These ‘exemptions’ also differ widely.  
2.4. INN PRESCRIBING IN BELGIUM 
The legal foundation for INN prescribing in Belgium was laid in 2001 [23] and it became practically possible in 
2005 (Figure 2) [24]. INN prescribing was defined as prescribing medicinal products using the active ingredient 
name, the corresponding strength and the method of administration (e.g. oral, injection, transdermal). The 
amount of units to be dispensed is determined by combination of the daily dose and the duration of treatment 
in weeks and/or days [24]. INN prescribing was introduced as an alternative way of prescribing to contribute to 
rational drug utilization. Related reimbursement policies obliged the pharmacist to dispense a generic product 
in response to an INN prescription. Therefore, INN prescribing could result in decreasing pharmaceutical 
expenditures for the government and the patient.  
Next to INN prescribing, two other important pharmaceutical policies, involving prescribing and reimbursement 
regulation, were introduced to promote rational drug utilization and the use of generics. These policies were (1) 
the reference price system and (2) quota for prescribing ‘cheap medicines’ (Figure 2) [25–27].  
The Belgian reference price system or nationally called the ‘reference reimbursement system’ started in June 
2001, with the aim to reduce the pharmaceutical expenditures of the health insurance institute. The reference 
reimbursement system established a common reimbursement price for all medicinal products belonging to the 
same group of interchangeable medicinal products (usually the reference product and its available generic 
products). This means that the health insurance does not reimburse more than the reference price for all 
General Introduction 
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medicinal products in each group. As a result, patients have to pay the difference when they are prescribed a 
medicinal product with its price above the reference price. This additional payment (added to the out-of-pocket 
fee) is called the ‘reference supplement’. Applying such a reference reimbursement system (1) decreases the 
demand for more expensive medicinal products and stimulates the use of cheaper ones (usually generic 
products) and (2) stimulates the price competition on the national pharmaceutical market [25,26]. 
At the end of 2005, quota for prescribing ‘cheap medicines’ were introduced, to further reduce the 
pharmaceutical expenditures of the health insurance, in order to make reimbursement of new, innovative 
medicinal products possible and to maintain low out-of-pocket expenditures for patients. These quota refer to a 
minimum percentage of ‘cheap medicines’ that have to be prescribed by physicians and dentists, on a yearly 
basis. ‘Cheap medicines’ are defined, in accordance with the reference reimbursement system, as (1) brand 
products with a reduced price, similar to the level of generic products, (2) generic products and (3) medicinal 
products dispensed with an INN prescription (regardless the type of medicinal product dispensed – a brand or 
generic product). The minimum percentage of ‘cheap medicines’ is determined based on the prescriber’s medical 
specialization [27–29]. 
Within the framework of the major rollout of electronic prescribing in Belgium, a project for the implementation 
of INN prescribing in electronic prescribing and the electronic medical file started in 2006 (Figure 2). The Ministry 
of Public Health requested the independent drug information center (Belgian Centre for Pharmacotherapeutic 
Information (BCFI/CBIP)) to coordinate the operationalization of electronic INN prescribing for outpatient care 
in daily medical practice.  
From the introduction of INN prescribing until the end of 2011, the total percentage of INN prescriptions 
constantly increased, but remained very low. At the end of 2006, 2.8 % of all prescriptions were written by INN 
Figure 2. Timeframe for the regulation of INN prescribing, the ‘reference reimbursement 
system’ and the quota for prescribing ‘cheap’ medicines in Belgium 
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(including those for which a brand product was dispensed). This percentage increased up to 3.3 % at the end of 
2008, was 6.6 % the end of 2010 and 7.5 % in December 2011 [30].   
In 2012, two new reimbursement policies involving INN prescribing were introduced (Figure 2). These policies 
were cost-containment measures, introduced in response to the global financial crisis, which started in 2008 and 
also affected Belgium [31].  
The first policy obliges the pharmacist to respond to an INN prescription by dispensing one of the three ‘cheapest’ 
medicinal products available. When patients insist on having their regular medicinal product dispensed, they do 
not obtain reimbursement and have to pay the full price of the medicinal product package. This policy started in 
April 2012. For determining the three ‘cheapest’ medicinal products, all reimbursable medicinal products are 
grouped together based upon their (1) active ingredient(s), the INN(s), (2) corresponding strength, (3) package 
size and (4) method of administration (e.g. solid oral, liquids). For each group, the price per unit was calculated 
to determine the three cheapest products available within a margin of 5 %. The list of cheapest products is 
updated every month [32,33].  
The second policy implies that all prescriptions for acute treatment with antibiotics or antifungal agents have to 
be considered as INN prescriptions. This means that the pharmacist is obliged to dispense one of the three 
cheapest medicinal products available, as described above. This policy is applicable to both brand name and 
branded generic name prescriptions. There are two situations where it is possible to deviate from this policy and 
have the prescribed medicinal product dispensed: (1) if the prescriber judges it is necessary for the sake and 
safety of the patient or (2) if the patient is allergic to an excipient with recognized action or effect [32,34]. These 
excipients with recognized action or effect are listed in a European guideline [35]. In both cases, the prescriber 
needs to indicate the reason for deviation on the prescription.  
The introduction of these last two policies, where INN prescribing was forced from an indicative way of 
prescribing into a cost-containment measure, was associated with quite some national media attention. It caused 
commotion and dissatisfaction, mainly by primary care health professionals, who worried about patient safety.  
2.5. CONTROVERSY OVER MEDICATION SWITCH 
Since their introduction, generic products have been subject to discussion in terms of their quality, methods to 
establish bioequivalence (BE) and interchangeability with brand products [36–39]. With the availability of generic 
products, generic substitution became also possible. Supply-side and demand-side pharmaceutical policies 
involving generic products and generic substitution have been implemented in order to control the increasing 
pharmaceutical expenditures [40]. Generic substitution and its related policy of (mandatory) INN prescribing are 
related to controversy and are extensively discussed in literature by proponents and opponents.  
Proponents can argue that BE is established using the appropriate methods described by regulatory authorities 
(e.g. European Medicines Agency (EMA), Food and Drug Administration (FDA) and Health Canada) [41–43] and 
that generic substitution can provide a more rational stock management in the pharmacy [44]. In some studies, 
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it was shown that patients are more likely to adhere to their treatment when their out-of-pocket fees are low 
[45] and that medication switch does not necessarily result in medication non-adherence [46]. However, it has 
also been shown that differences in medication appearance due to switching influence medication adherence 
negatively [47,48]. Some studies indicate that a proper explanation by primary care health professionals can 
avoid confusion and mistrust when initiating medication switch and that the more medication switches occur, 
the less patients are reluctant [49–51]. In contrast, many case reports are available in literature describing issues 
potentially related to medication switch [52–57]. 
Opponents can use the available case reports for their argumentation, but should also take into account the 
studies which failed to show important differences in clinical outcomes due to switching [47,48]. Opponents 
claim that the applied limits for establishing BE (80 – 125 %) allow too much variation, in particular for narrow-
therapeutic index drugs (NTIDs) [58–60]. However, an important review performed by the FDA demonstrated 
that in almost 98 % of the reviewed BE studies the difference between brand and generic product was only 10 % 
[61,62]. In anticipation of these concerns, some regulatory authorities (e.g. EMA) tightened the limits for BE 
establishment of NTIDs [41] and national authorities exempted different (groups of) products from generic 
substitution and/or INN prescribing (e.g. antiepileptic drugs (AEDs), immunosuppressive agents) [63–65]. 
Another common point of criticism is that BE studies have only been performed in a limited number of healthy 
volunteers and that their results cannot be extrapolated to patients [44,57,58]. Opponents report that there are 
currently no pharmaco-economic studies available to demonstrate the cost-benefit ratio for generic substitution 
[60]. In addition, it is frequently commented that extra costs related to ADRs and therapy failure due to 
medication switch can outweigh the benefits and cost-savings [38,66–69].  
Finally, issues related to medication switch can have different origins. Differences in pharmacokinetic (PK) and 
pharmacodynamic (PD) parameters can result in altered clinical outcomes and serious consequences, which are 
more likely to appear with NTIDs. However, it is suggested that these differences are probably not the only reason 
for therapy failure after medication switch [11,44,49,57,60,70,71]. There is evidence that differences in 
medication appearance (e.g. change in color) contributes to patient confusion and uncertainty and result in 
medication non-adherence [72,73].  
All these studies and arguments indicate that different elements should be taken into account when considering 
a medication switch, in order to contribute to cost-savings and assure patient safety and that finding a good 
balance between both is a big challenge.  
  
General Introduction 
23 
 
3. ELECTRONIC PRESCRIBING 
Electronic prescribing refers to making a prescription with a computerized tool and sending it to the pharmacy 
as a telematic message. In this way, it is possible to generate an accurate, error-free and understandable 
prescription [74]. Electronic prescribing differs from making a paper prescription with a computerized tool.  
Electronic prescribing plays an important role in the strategy to improve health care and facilitate patient 
mobility across Europe [22,74]. Currently, electronic prescribing is widely used in Denmark, Sweden and the 
Netherlands and it is being progressively implemented in other European countries such as England, Estonia, 
Iceland and Scotland [74].  
For Belgium, the first initiative towards electronic prescribing in outpatient care was taken in 2001, with an 
explorative study. Additional studies and working group meetings were performed until the ‘Recip-e’ project 
started in 2007. The main objectives for the ‘Recip-e’ project were (1) to allow free choice of health care provider 
for the patient and (2) to create a generic system which can be used for prescribing medicinal products, 
physiotherapy, nursing care, clinical biology tests and medical imaging [75,76]. All data exchange is performed 
via the national eHealth platform [77]. Starting from 2013, the electronic prescription is being gradually 
implemented in Belgium and national roll-out of the electronic prescription for medicinal products was 
announced in March 2014 [75,76].  
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4. PROBLEM STATEMENT & SCOPE 
International Nonproprietary Name (INN) prescribing is a way of prescribing with legal foundation in many 
European countries, also in Belgium. Despite its potential as rational way of prescribing, it did not really found 
foothold in continental Europe. However, in response to the global financial crisis, many countries forced INN 
prescribing into a cost-containment measure. Based upon and reflecting the countries’ traditional attitudes 
towards providing and financing health care, INN prescribing is implemented in various ways and extents in 
European countries. In Europe and Belgium, different aspects of INN prescribing contributing to rational drug 
utilization have been discovered, but not all of its potential is fully exploited.  
Therefore, the aims of this thesis are to investigate: 
1. How INN prescribing was operationalized in Belgium for the implementation in electronic prescribing 
and the electronic medical record (Chapter 1); 
2. How the important policy changes involving INN prescribing in spring 2012 were received by Flemish 
general practitioners and pharmacists (Chapter 2); 
3. How the important policy changes involving INN prescribing in spring 2012 were received by Flemish 
medicine students and pharmacy students (Chapter 3); 
4. How and to which extent INN prescribing (and related generic substitution) is regulated and 
implemented in European countries; and to compare the exemptions applied to this regulation (Chapter 
4); 
5. Whether there is a pharmacokinetic reason for exempting certain medicinal products from INN 
prescribing and/or generic substitution, by performing a clinical trial and using the appropriate 
bioequivalence method (Chapter 5).  
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5. OUTLINE 
In the next five chapters, we present the results of our research in line with the aims.  
In Chapter 1, we present the process, principles and results of the operationalization project for the 
implementation of electronic INN prescribing in Belgium. We describe the resulting operational rules and 
reference database to be implemented in commercial software.  
In Chapter 2, we present the results of our questionnaire study which aimed to explore the attitudes of general 
practitioners and pharmacists in Flanders, towards the current way of INN prescribing.  
In Chapter 3, we present the same topic as in Chapter 2 for medicine students and pharmacy students.  
In Chapter 4, we present an overview of the different ways and extent INN prescribing (and its related policy 
generic substitution) is applied in 16 European countries. Additionally, we describe and compare the main 
(groups of) medicinal products exempted from these concepts.  
In Chapter 5, we present the results of our clinical trial performed in 30 healthy volunteers to investigate 
individual bioequivalence of gabapentin 800 mg tablets, a medicinal product which is advised not to be switched 
in Belgium.  
Finally, we integrate our results in the general discussion. We address some issues related to INN prescribing in 
Belgium and Europe and we make suggestions for improvements and changes in order to make INN prescribing 
a fully accepted way of prescribing.  
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ABSTRACT 
Objective.  The aim is to describe the process, principles and results of the International Nonproprietary Name 
(INN) prescribing project in Belgium. The purpose of this project was to operationalize electronic INN prescribing 
for outpatient care in daily medical practice and to develop a factual database which can be used in electronic 
INN prescribing applications.  
Methods. The operationalization process consisted of three phases: (1) expert consultation, (2) review by 
regulatory authorities and (3) test phase with stakeholders and end-users.   
Results. The INN prescribing project resulted in (1) operational rules for electronic INN prescribing, and (2) a 
reference database to be implemented in commercial medical software. The operational rules for electronic INN 
prescribing define valid INN groups as sets of equivalent medicinal products, described by three elements: the 
therapeutic moiety (the active part of the therapeutic ingredient) or combination of therapeutic moieties, the 
strength (with standardized denominators), and the method of administration (with simplified but standardized 
options). The operational rules also define two categories of exemptions for INN prescribing: INN groups where 
the first choice of treatment should be continued throughout the therapy period (NO SWITCH) and medicinal 
product groups not suitable for INN prescribing (NO INN). The reference database is the result of the virtual 
classification of the Belgian therapeutic arsenal into INN groups, according to the operational rules.  
Conclusion. Defining the operational rules for INN prescribing for and with different stakeholders was a difficult 
yet feasible assignment. The INN prescribing project resulted in explicit operational rules and a reference 
database. The Belgian experience may provide important information for other countries planning to 
operationalize or refine electronic INN prescribing. It can also be used for a thorough evaluation of the impact of 
the new concept of INN prescribing on daily practice and on medical education. 
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1.1. INTRODUCTION 
International Nonproprietary Names (INNs) were introduced by the World Health Organization (WHO) in 1950 
as a global, internationally accepted nomenclature for active ingredients and pharmaceutical substances [1]. This 
nomenclature is an alternative to the management of proprietary brand names, supported by the World 
Intellectual Property Organisation (WIPO) [2]. It was developed to facilitate the identification of medicines, the 
exchange of information such as pharmacovigilance data, and the communication amongst health professionals 
[1]. The concept of “INN prescribing” is defined as using the INN instead of the brand name for prescribing [1,3,4]. 
INN prescribing is said to contribute to rational drug choice and drug utilization [4]. Using the INN for prescribing 
may also prevent prescribing and dispensing errors [1] by increasing prescribers’ and pharmacists’ awareness of 
the prescribed active ingredient and the corresponding strength. INN prescribing has recently been promoted as 
a strategy to reduce pharmaceutical expenditures [5]. It has been extensively adopted by different countries, 
with 22 of the 27 member states of the European Union providing a legal foundation for INN prescribing [5].  
The concept of INN prescribing is operationalized in different ways and various degrees in several countries. This 
variation in operationalization may be explained by the broad definition of INN prescribing, by differences in 
health care systems and in legal formats of prescriptions. Differences in drug policies, such as reference price 
systems, reimbursement and generic substitution policies, and therapeutic arsenals (i.e. all medicinal products 
marketed in a country) may also contribute to this variation. All this makes cross-national comparison complex.  
In Belgium, the legal foundation for INN prescribing was laid in 2001 but it lasted until 2005 before INN 
prescribing was officially allowed in clinical practice [6]. By the end of 2007, INN prescribing was poorly adopted 
in Belgium with only 5.1 % INN prescriptions [7]. Given the low uptake and the upcoming major rollout of 
electronic prescribing, the Ministry of Public Health requested the Belgian Centre for Pharmacotherapeutic 
Information (BCFI/CBIP, the independent drug information centre in Belgium) at the end of 2006, to coordinate 
“the INN prescribing project”. The purpose of this project was to operationalize electronic INN prescribing for 
outpatient care in daily medical practice and to develop a factual database which can be used in electronic INN 
prescribing applications. The objectives were (1) to convert the legislation into operational rules for electronic 
INN prescribing and (2) to develop a reference database for INN prescribing to be implemented in commercial 
medical software.  
The aim of this paper is to describe the process, principles and results of the INN prescribing project in Belgium. 
1.2. METHODS 
The development process of the INN prescribing project consisted of three phases (Figure 1.1): (1) expert 
consultation, (2) review by regulatory authorities, and (3) test phase with stakeholders and end-users.  
In the first phase a group of external experts engaged in a series of five structured meetings with the goal to 
formulate a first draft of the operational rules. The group met at monthly intervals, for two-hour meetings. 
Members were experts from the independent drug information centre (BCFI/CBIP); the medicines agency, i.e. 
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the regulatory authority for medicines (the Federal Agency for Medicines and Health Products (FAMHP) including 
the Medicines Commission for Medicines for human use which is responsible for the marketing authorization of 
medicines for human use); public health (Federal Public Service for Health, Food Chain Safety and Environment); 
the health insurance institute (National Institute for Health and Disability Insurance (RIZIV/INAMI)); scientific 
associations of general practitioners and pharmacists, and experts in medical informatics from the software 
vendors. The experts started with reviewing literature on INN prescribing, analysing the legislation, and making 
an inventory of existing initiatives in Belgium concerning INN prescribing. Important findings were structured 
into different issues, which were discussed. The results of these discussions formed the basis of the draft 
document for the operational rules. At the same time, the group of external experts elaborated a classification 
of the Belgian therapeutic arsenal based on the draft operational rules. This virtual classification was the 
preliminary work for the development of the reference database. 
Figure 1.1. Timeline for the INN prescribing project 
 
The goal of the second phase was obtaining the approval for the draft operational rules from the Medicines 
Commission, which is the decision-making body within the medicines agency. The approval process was prepared 
by executives from the medicines agency, and the Medicines Commission, while experts from the independent 
drug information centre were only attending to coordinate the approval process. The executives and experts 
gathered five times, at monthly intervals, to discuss the draft operational rules and the classification of the 
therapeutic arsenal. After they had reached an agreement, representatives from the health insurance institute 
were asked to comment the operational rules. The final version of the operational rules was approved by the 
Medicines Commission [8].  
In the third phase, the operational rules and the reference database were made accessible via an internet 
application for stakeholders and end-users, such as physicians, pharmacists and, ethical pharmaceutical industry 
(pharmaceutical companies developing new molecules) and generic pharmaceutical industry. During a one-year 
pilot phase, the reference database was tested and checked for applicability and inconsistencies. Comments 
were sent to the independent drug information centre. Relevant items were discussed and adjustments were 
made to the operational rules and the reference database. The adjustments were officially approved for the 
second time by the Medicines Commission for Medicines for human use.  
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1.3. RESULTS 
1.3.1. OPERATIONAL RULES 
The group of external experts proposed to expand the concept of INN prescribing in order to implement it in 
electronic prescribing. They recommended the use of three key elements instead of one (the INN) to make a 
valid electronic INN prescription: (1) the therapeutic moiety or combination of therapeutic moieties, (2) the 
strength and, (3) the method of administration [8]. These three key elements are used to describe a set of 
equivalent medicinal products, called an ‘INN group’ (Figure 1.2). For example, all products marketed in Belgium 
containing alprazolam 2 mg tablets – Alprazolam Mylan® 2 mg, Alprazolam Teva® 2 mg, Alprazolam EG® 2 mg 
and Xanax® 2 mg – are classified in the same INN group ‘Alprazolam 2 mg (oral)’ (Figure 1.2a). Applying this way 
of classification to the 7 319 medicinal product packages available on the Belgian market in July 2012, resulted 
in 6 732 (92.0 %) medicinal product packages being suitable for INN prescribing, and being classified into 2 765 
INN groups. The remaining 587 (8.0 % of the Belgian therapeutic arsenal) medicinal product packages are 
exempted from INN prescribing (NO INN) (see 1.3.5. for further description). Each of the INN groups is identified 
by a standardized label and has a unique identification number.  
Prescribers can make an unambiguous INN prescription by specifying and prescribing the label of the INN group. 
At the same time, the unique identification number is registered in the patient’s electronic medical record. 
Additional specifications can be indicated to the INN group to ensure the dispensing of products with specifically 
desired characteristics (e.g. divisible tablets) (Figure 1.2a). Finally, the Belgian legislation [6] states that the 
amount of product that has to be dispensed should be determined by combination of daily dose and duration of 
treatment (e.g. 1 tablet per day during 3 months), which is in contrast to prescribing by product name where the 
package size is indicated (e.g. 90 tablets). All this led to a more explicit definition of INN prescribing for Belgium: 
INN prescribing is using the INN, indicating the corresponding strength and the method of administration and, 
defining the amount of units to be dispensed by combination of daily dose and duration of treatment. In response 
to an INN prescription, the pharmacist will chose a medicinal product package which complies with the 
prescription specifications. The dispensed product is usually a generic, when available. If no generics are available 
or if the price of the brand is very low, the dispensed product might be a brand. 
1.3.2. OPERATIONALIZATION OF THE THREE KEYS ELEMENTS 
THERAPEUTIC MOIETY 
To represent the active ingredient of the medicinal product, the INN nomenclature served as a basis to select the 
options for the first key element. This element is called ‘therapeutic moiety’ rather than INN, to indicate a more 
abstract representation of the active ingredient. ‘Therapeutic moiety’ can be defined as the therapeutic active 
part of a molecule. The basis for the operationalization of this element was also drawn from the ‘dictionary of 
medicines + devices’ (dm+d), developed by the National Health Service (NHS) in the United Kingdom [9] and,  
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Figure 1.2. The INN group principle and the decision-support illustrated by (a) alprazolam divisible tablets,  
(b) ceftazidime I.M. injection and (c) gabapentin capsules 
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from the Periodic Safety Update Report (PSUR) synchronization list, made by the Heads of Medicines Agencies 
(HMA) [10].  
The INN nomenclature is a mix of names for bases, acids, alcohols, salts and esters [1]. Unless there was strong 
evidence for clinical relevance, it was decided to restrict the name of the first key element to the name of the 
base or acid. For example, it was shown by different studies that the two different salts of perindopril, tert-
butylamine and arginine, are bioequivalent. Therefore the name of the therapeutic moiety was restricted to 
‘perindopril’ [11,12]. The same applies to: amlodipine, metoprolol, diclofenac and piroxicam. In contrast, the full 
name of the active ingredient was kept for hydrocortisonacetate and hydrocortisonbutyrate when representing 
the first key element, because of major difference in potency between both [13]. 
A multilingual reference table was developed containing all therapeutic moieties needed to classify the Belgian 
therapeutic arsenal into INN groups. Basic information in English (INNs [14], dm+d [9], and the PSUR 
synchronisation list [10]) and in French (INNs [14]) was used to select the options for the therapeutic moieties in 
these languages. Because no basic information was available in Dutch, the independent drug information centre 
provided the official translation of the therapeutic moieties in Dutch.  
The first key element can also be a combination of different therapeutic moieties, e.g. amoxicillin + clavulanic 
acid, provided this combination is instantiated by a medicinal combination product, which is mentioned on the 
PSUR synchronization list, and currently available on the Belgian market. 
STRENGTH 
The strength of the therapeutic moiety represents the second key element of the INN group and is defined by 
the one listed in the marketing authorization file of the corresponding medicinal products in the INN group. In 
case different strengths are registered for the same therapeutic moiety, because of differences in salts and 
esters, it was decided by consensus which strength was represented. For instance, the therapeutic moiety 
perindopril is registered as perindopril tert-butylamine 4 mg and perindopril arginin 5 mg, because of the 
difference in molecular weight. Perindopril tert-butylamine 4 mg and perindopril arginine 5 mg contain an 
equimolar amount of perindoprilat (the active metabolite of perindopril) [11]. Therefore, all medicinal product 
packages containing both doses were classified into the same INN group ‘Perindopril 4 mg (oral)’. Representing 
the strength as 4 mg, instead of 5 mg, was a consensus decision.  
Pharmaceutical forms were grouped into ten categories (Table 1.1). For each category, a denominator was 
chosen to express the strength. The strength of all solid forms (e.g. tablets, capsules, suppositories) is expressed 
(in mg or g) per unit. The strength of single dose injection vials and vials for infusion is expressed per vial, and 
the strength for inhalers is expressed per dose. These denominators are implied, and therefore not mentioned, 
when representing the strength in the INN groups. In the other categories, the strength is expressed as a 
concentration per mL or per g, and the denominator is mentioned when representing the strength.  
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Table 1.1. Denominators to express the strength of pharmaceutical forms 
Categories of pharmaceutical forms Denominator 
Solid forms (e.g. tablets, capsules, suppositories) Per unit 
Syrups & drinks Per mL 
Drops (for oral use) Per mL 
Vial for injection – single dose Per vial 
Vial for injection – multi dose Per mL 
Vial for infusion Per vial 
Topical preparations:  
• Solid & semi-solid 
• Liquid 
Per g 
Per mL 
Transdermal delivery systems Per time unit (e.g. per hour, per 24 hours, …) 
Inhalers Per dose 
For injectable products, a distinction was made between single and multiple dose vials. For single dose vials, the 
total amount of therapeutic moiety was used to express the strength, regardless of the concentration, an 
approach similar as in solid forms (Figure 1.2b). The same applies to vials for infusion. By contrast, for multiple 
dose vials, the strength was expressed as the concentration of the therapeutic moiety (and the total volume of 
the vial indicates the package size).  
METHOD OF ADMINISTRATION 
In 95 % of the cases, the combination of the therapeutic moiety and strength is sufficient to create unambiguous 
INN groups containing equivalent medicinal products. To handle the remaining 5 % of the medicinal products 
(e.g. diclofenac 100 mg tablets and diclofenac 100 mg suppositories), the ‘method of administration’ was 
introduced as the third key element. Using the list with standard terms for ‘routes and methods of 
administration’ [15] and ‘dosage forms’ [16] from the European Pharmacopeia, a list with 36 options for the third 
key element was created. Out of the 74 terms for human use on list of the European Pharmacopeia, 16 terms 
were selected. They were complemented with 7 new terms (Table 1.2).  
The first term added was ‘injection’ to summarize all products that can be administered by injection or by 
injection (e.g. intravenous, intramuscular) ánd by infusion. Secondly, the term ‘infusion’ was reserved for those 
products that can only be administered by infusion (e.g. Zinacef® 1.5 g powder for solution for infusion). The 
term ‘nebulization’ was added for inhalation products that have to be nebulized (e.g. Ventolin® Respirator 
solution 5 mg/mL).  
The term ‘oral’ is used for oral medicinal products, and no distinction was made for products with a fast releasing 
profile (e.g. instant tablets). In contrast, for medicinal products with prolonged release two new terms were 
created: ‘oral, prolonged release 1x per day’ for those that have to be taken only once a day and ‘oral, prolonged 
release’ for those that have to be taken more than once a day. Similarly, the terms ‘injection, prolonged release’ 
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for depot injections and ‘ophthalmological, prolonged release’ for eye products with prolonged release were 
introduced to guarantee homogeneous INN groups.  
Finally, the list was completed with 13 combinations of single terms for INN groups containing medicinal products 
that can be administered via different methods (Table 1.2). For example, isosorbide dinitrate 5 mg tablets 
(Cedocard®) for angina pectoris can be administered orally or sublingually and therefore the third key element 
for this INN group is ‘oral/sublingual’.  
Table 1.2. Single term options for the third key element ‘method of administration’ in English, Dutch & French 
and combination term options in English 
English Dutch French 
Auricular Auriculair Auriculaire 
Cutaneous Cutaan Cutané 
Dental Dentaal Dentaire 
Endocervical Endocervicaal Endocervical 
Infusion* Infuus* Perfusion* 
Inhalation Inhalatie Inhalation 
Injection* Injectie* Injection* 
Injection, prolonged release* Injectie, verlengde vrijstelling* Injection, libération prolongée* 
Intrauterine Intra-uterien Intra-utérine 
Intravesical Intravesicaal Intravésicale 
Nasal Nasaal Nasal 
Nebulization* Nebulisatie* Nébulization* 
Ophthalmological Oftalmologisch Ophtamologique 
Ophthalmological, prolonged 
release* 
Oftalmologisch, verlengde 
vrijstelling* 
Ophtalmologique, libération 
prolongée* 
Oral Oraal Oral 
Oral, prolonged release* Oraal, verlengde vrijstelling* Oral, libération prolongée* 
Oral, prolonged release, 1x per 
day* 
Oraal, verlengde vrijstelling, 1x 
per dag* 
Oral, libération prolongée, 1x par 
jour* 
Oropharyngeal Orofangyngeaal Bucco-phangyngée 
Rectal Rectaal Rectal 
Sublingual Sublinguaal Sublingual 
Transdermal Transdermaal Transdermal 
Urethral Urethra Urethra 
Vaginal Vaginaal Vaginal 
Combination terms: Cutaneous/vaginal • Infusion*/intravesical • Injection*/infusion* • Injection*/inhalation 
• Injection*/intravesical • Injection*/oral • Injection*/rectal • Ophthalmological/auricular  • 
Ophthalmological/auricular/nasal • Oral/oropharyngeal/cutaneous • Oral/rectal • Oral/sublingual • 
Oropharyngeal/nasal 
*terms introduced to suit the Belgian therapeutic arsenal 
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1.3.3. ADDITIONAL SPECIFICATIONS AND INFORMATION 
To have the most suitable product dispensed to the patient, the prescriber can add certain specifications, in 
addition to the INN group, to the prescription (Figure 1.2a, 1.2b). The following specifications were included on 
the level of the medicinal product package, in the reference database, if relevant: 
1) specific route(s) of administration (e.g. intravenous, intramuscular, subcutaneous) 
2) divisibility of solid forms 
3) solubility of solid forms (e.g. effervescent tablets)  
4) enteric coated solid forms 
5) the vehicle for topical products (e.g. cream, ointment, paste) 
6) excipients known to have a recognized action or effect (e.g. glucose, lactose) (the implementation 
of this specification is currently under construction) 
When making an INN prescription for a topical product, the prescriber is obliged to choose one of the available 
vehicles, if relevant.  
The European guideline “Excipients in the label and package leaflet of medicinal products for human use” 
provides a list of excipients known to have a recognized action or effect [17]. Only the excipients mentioned in 
the European guideline will be included in the reference database. Currently, this is only achieved for antibiotics 
and antifungal products available for outpatient care.  
Finally, it was decided to include a link to information, on the medicinal product package level, regarding the 
therapeutic indication and the reimbursement of products. Indeed, within the same INN group, the official 
therapeutic indications (as mentioned in the Summary of Product Characteristics) as well as the reimbursement 
criteria may slightly differ between medicinal product packages within one INN group.   
1.3.4. INN GROUPS WHICH REQUIRE SPECIAL ATTENTION (NO SWITCH) 
To guarantee patient safety when prescribing by INN, the ‘NO SWITCH’ label for INN groups was created. This 
label means that medicinal products in these groups can be prescribed by INN, but once treatment is started 
with a product from a particular manufacturer, it is advised to continue treatment with exactly the same product 
(Figure 1.2c). However, switching between products during treatment is not impossible, but has to be done 
carefully and under the supervision of the prescriber.  
The label was given to INN groups containing (1) medicinal products with a narrow therapeutic index (NTI) and/or 
(2) very toxic molecules (Table 1.3). Within the European Union, there is no official definition of a drug with a 
narrow therapeutic index. The European Medicine Agency (EMA) states in its ‘Guideline on the Investigation of 
Bioequivalence’ that “It is not possible to define a set of criteria to categorise drugs as narrow therapeutic index 
drugs (NTIDs) and it must be decided case by case if an active substance is an NTID based on clinical 
considerations.” [18]. Therefore, the definitions of the Canadian and American authorities were also consulted. 
The Guidance for Industry concerning bioequivalence requirements on critical dose drugs from Health Canada 
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defines critical dose drugs as “those drugs where comparatively small differences in dose or concentration lead 
to dose-and concentration-dependent, serious therapeutic failures and/or serious adverse drug reactions which 
may be persistent, irreversible, slowly reversible, or life threatening, which could result in inpatient hospitalization 
or prolongation of existing hospitalization, persistent or significant disability or incapacity, or death. Adverse 
reactions that require significant medical intervention to prevent one of these outcomes are also considered to 
be serious.”[19]. The Centre for Drug Evaluation and Research (CDER) from the Food and Drug Administration 
(FDA) gives the following definition of narrow therapeutic index: “there is less than a 2-fold difference in the 
minimum toxic concentrations and minimum effective concentrations in the blood and safe and effective use of 
the drug products require careful titration and patient monitoring.” [20].  
Table 1.3. Pharmaceutical products and categories with the ‘NO SWITCH’ label 
NTIDs and/or very toxic molecules or antiepileptic drugs 
Acenocoumarol 
Amiodarone 
Azathioprine 
Carbamazepine* 
Cibenzoline 
Clozapine 
Colchicine 
Cyclosporin 
Digoxin 
Disopyramide 
Ethosuximide* 
Everolimus 
Felbamate* 
Flecainide 
Gabapentin** 
Lacosamide** 
Lamotrigine** 
Levetiracetam** 
Levothyroxin 
Lidocaine 
Lithium 
Metildigoxin 
Mycophenolate 
Oxcarbazepine** 
Pheneturide* 
Phenobarbital* 
Phenprocoumon 
Phenytoin* 
Pregabalin** 
Primidone* 
Propafenone 
Sirolimus 
Sotalol 
Stiripentol** 
Tacrolimus 
Theophyllin 
Tiagabine** 
Topiramate** 
Valproate* 
Valproic acid* 
Vigabatrin** 
Warfarin 
   
Other categories of pharmaceutical products 
Oral contraceptives 
Mesalazine and sulphasalazine 
Inhalation medication for pulmonary use 
Medicines used in oncology 
Transdermal delivery systems 
Diagnostics and anesthetics 
Pharmaceutical products for local use (e.g. dermatological products) 
*Antiepileptics (NTID and/or very toxic) 
**Antiepileptics (not NTID and/or very toxic) 
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The Belgian list of therapeutic moieties with NTI and/or very toxic was defined by the experts from the medicines 
agency, based on the preceding definitions, existing lists of products with NTI from Health Canada [19], the FDA 
[21] and the Danish Medicines Agency [22], reference books and websites such as Goodman & Gilman [23], 
Micromedex [24] and Medline Plus [25], information from The International Association of Forensic Toxicologists 
(TIAFT) [26] and expert opinions. 
All antiepileptics on the Belgian market were considered as NO SWITCH. Most of them because they are drugs 
with a NTI and/or very toxic molecules (Table 1.3). However, also others (gabapentin, lacosamide, lamotrigine, 
levetiracetam, oxcarbazepine, pregabalin, stiripentol, tiagabine, topiramate and vigabatrine) are listed as NO 
SWITCH for precautionary reasons as in literature potential problems were reported, possibly related to 
switching between products of different manufacturers during treatment. 
Other INN groups were also considered as NO SWITCH for various reasons (Table 1.3). For example, because of 
lack of evidence of bioequivalence between products (e.g. mesalazine and sulphasalazine), the complex 
pharmacotherapeutic profile (e.g. diagnostics and anesthetics), complex packaging (e.g. oral contraceptives) or 
because of precautionary measures with regard to toxicity (e.g. medicines used in oncology). 
Out of all 2 765 INN groups, 794 groups were given the NO SWITCH label (28.7 %), which corresponds to 1 528 
medicinal product packages of the 7 319 packages (20.9 %) available on the Belgian market.  
1.3.5. PRODUCTS EXEMPT FROM INN PRESCRIBING (NO INN) 
Finally, three categories of medicinal products were exempted from INN prescribing: (1) biologicals, including 
biosimilars, (2) medicinal products containing more than three therapeutic moieties, and (3) multiphasic 
contraceptive pills.  
Biologicals, including biosimilars, were deemed not suitable for INN prescribing because of their molecular 
complexity [27] and the risks associated to their immunogenicity when switching [28]. The medicines agency 
provides, on its website, a list of all biologicals and biosimilars available on the Belgian market [29].  
Medicinal products with more than three therapeutic moieties were exempted because of the complexity when 
prescribed by INN (e.g. complex polyvitamins). Similar for multiphasic contraceptive pills because of the 
complexity of packaging.  
It is important to note that although these products are deemed not suitable for INN prescribing, it is still possible 
for the prescriber to start treatment with a generic medicine, when one is available, by prescribing the branded 
generic name. 
Out of all 7 319 medicinal product packages available on the Belgian market, 587 of them are not suitable for 
INN prescribing (8.0 % of the therapeutic arsenal).  
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1.3.6. REFERENCE DATABASE 
The reference database (Figure 1.3) [30] includes all 7 319 medicinal product packages available on the Belgian 
market: 6 732 packages suitable for INN prescribing which are classified into 2 765 INN groups (including the 794 
INN groups with the NO SWITCH label) and the remaining 587 packages exempted from INN prescribing (NO 
INN). For each medicinal product package it was determined (1) whether it can be prescribed by INN, (2) to which 
INN group it belongs, and (3) which additional specifications apply.  
The reference database can be consulted at www.bcfi.be/inn, and contains all relevant information on the level 
of medicinal product packages, such as route of administration, divisibility, solubility, enteric coated, vehicles for 
topical products and excipients known to have a recognised action or effect (this latter aspect is currently under 
construction). Links to information on the therapeutic indications and reimbursement were added. For INN 
groups containing the NO SWITCH label, the main reason for having this label was indicated (e.g. medicines used 
in oncology).  
All included information on the medicinal product packages allows the database to serve as a decision-support 
tool to foster safe and efficient medicines prescribing and dispensing. When prescribing by INN, the prescriber 
follows a step by step process, starting by choosing the therapeutic moiety (Figure 1.2). Next, all possible options 
for the strength and the method of administration are shown and the most suitable one has to be selected. When 
available, additional specifications (e.g. dispensed product needs to be divisible) can be added to have the 
desired product dispensed to the patient. Similarly, the pharmacist is guided to dispense the most suitable 
product. The drug choice process is complex [31,32], and literature has already shown the positive effect of 
decision-support and computerized drug order entry (CDOE) on preventing prescribing and dispensing errors 
[33–35]. For practical reasons, a search strategy was added by which the user can enter a specific product name 
to find the corresponding INN group.  
The reference database is kept up to date by the independent drug information centre and will also be integrated 
in the authentic source of medicines on the eHealth platform [36,37]. The reference database is available for 
medical software vendors to integrate in their prescription and dispensing software. 
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Figure 1.3. Screenshot from the reference database 
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1.4. DISCUSSION 
To our best knowledge, this study is the first to provide a transparent description of the operationalization 
process of INN prescribing, resulting in explicit operational rules and a publically available database.  
INN prescribing is frequently used as a strategy to reduce pharmaceutical expenditures. However, in Belgium, 
several strategies such as the well-established reference price system [38,39] and the encouragement of 
prescribers to prescribe cheap products (either generics or originators in case they lowered their prices to the 
reference price) were already introduced as cost-saving measures before INN prescribing came into force. 
Therefore, the emphasis of the INN prescribing project was more on rational drug choice and operationalizing 
the concept for electronic prescribing, rather than on cost-savings. In retrospect, we believe that structuring the 
development process was essential to achieve consensus on this complex matter, with a variety of stakeholders 
with different interests. 
The operationalization of INN prescribing in Belgium resulted in four important achievements.  
The first achievement was the publication of explicit operational rules, accepted by the governing bodies and the 
stakeholders, making the approach transparent. 
The second achievement was the development of a high level categorization of ‘method of administration’, based 
on dosage forms and route of administration.  
Third was the agreement on an explicit list of therapeutic moieties with NTI and/or being very toxic.  
Finally, the fourth achievement was the development of a publically available database, which classifies all 
medicinal product packages in the Belgian therapeutic arsenal, allowing correct registration of an INN 
prescription in the electronic medical record through a unique identification number, which was not possible 
before. In addition, this database provides reliable information for decision-support systems to foster efficient 
and rational drug choice in prescribing and dispensing.   
Next to achievements, this project also has its limitations.  
First, decisions to make homogeneous INN groups, to label some INN groups which require special attention (NO 
SWITCH), and to exempt certain products from INN prescribing (NO INN) were made in accordance to the best 
available evidence, which was sometimes limited. There was also an attempt to meet all the different interests 
from all the stakeholders, such as the ethical and generic pharmaceutical industry, the authorities and 
professional associations. Hence, the first limitation is that the reference database may be perceived in some 
aspects as country-specific and subjective.  
Second, up to now, the project only focussed on INN prescribing for outpatient care. The developed operational 
rules need to be adjusted to fit the complex character of medicinal products for inpatient care and the 
classification of the therapeutic arsenal and the reference database need to be complemented with hospital 
drugs. 
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A few points need further attention. 
First, there is the inconsistency between the Belgian laws on INN prescribing [6] and controlled drugs [40,41]. 
Controlled drugs can be prescribed by brand name or by INN, but the law on controlled drugs obliges the 
prescriber to specify the total amount of product that has to be dispensed and write it in full (e.g. thirty tablets, 
and not 30 tablets). This latter aspect is in contrast to how the amount of product has to be determined when 
prescribing by INN, being by combination of daily dose and duration of treatment. The consequence for 
prescribing controlled drugs by INN is that a package size (expressed in full writing) needs to be chosen.  
Second, for pro re nata (PRN) use (if-needed use) it is difficult to determine the number of intakes and the 
duration of treatment. As result the amount of product that has to be dispensed cannot be determined in 
advance. Therefore, it might be appropriate to indicate a maximum amounts of units to be dispensed.  
Third, it should be explored whether it is possible to provide feedback to the prescriber on the exact nature of 
the dispensed medicinal product package, in case of INN prescribing. This can prevent information gaps for the 
prescriber in situations where characteristics of the medicinal product package (e.g. colour, taste, package size) 
might be important (e.g. the identification of ingested drugs in voluntary or involuntary poisoning).  
Fourth, it remains to be seen whether co-operation between stakeholders can be continued for the maintenance 
of the operational rules to ensure consistency with new policies influencing (electronic) INN prescribing.  
Finally, the impact of this new concept should be rigorously tested, as well in the daily practice of prescribing and 
dispensing medicines, as in medical education for rational pharmacotherapy.   
1.5. CONCLUSION 
Defining the operational rules for INN prescribing for and with different stakeholders was a difficult yet feasible 
assignment. The INN prescribing project resulted in explicit operational rules and a reference database. The 
Belgian experience may provide important information for other countries planning to operationalize or refine 
electronic INN prescribing. It can also be used for a thorough evaluation of the impact of the new concept of INN 
prescribing on daily practice and on medical education. 
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ABSTRACT 
Objective. International Nonproprietary Name (INN) prescribing is the use of the name of the active ingredient(s) 
instead of the brand name for prescribing. In Belgium, INN prescribing started in 2005 and a major policy change 
occurred in 2012. The aim was to explore the opinions of Dutch-speaking general practitioners (GPs) and 
pharmacists.  
Methods. An electronic questionnaire with 39 5-point Likert scale statements and one open question was 
administered in 2013. Multivariate analysis was performed with multiple linear regression on a sum score for 
benefit statements and for drawback statements. Answers to the open question were qualitatively analyzed.  
Results. We received 745 valid responses with a representable sample for both subgroups. Participants perceived 
the motives to introduce INN prescribing as purely economic (to reduce pharmaceutical expenditures for the 
government and the patient). Participants accepted the concept of INN prescribing, but 88 % stressed the 
importance of guaranteed treatment continuity, especially in older, chronic patients, to prevent patient 
confusion, medication nonadherence and erroneous drug use.  
Conclusion. The current way INN prescribing is applied in Belgium leads to many concerns among primary health 
professionals about patient confusion and medication adherence. Slightly adapting the current concept of INN 
prescribing to these concerns can turn INN prescribing into one of the major policies in Belgium to reduce 
pharmaceutical expenditures and to stimulate rational drug prescribing.  
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2.1. INTRODUCTION 
In an international setting, International Nonproprietary Name (INN) prescribing is defined as using the name of 
the active ingredient(s) instead of the brand name for prescribing [1–3]. International Nonproprietary Names 
(INNs) belong to an official nomenclature for active ingredients in the pharmaceutical domain. This is the result 
of a collaboration between the World Health Organization (WHO), which governs this public nomenclature, and 
the World Intellectual Property Institute (WIPO), which governs the brand names of pharmaceutical products [4–
6]. INNs were developed to facilitate the identification of medicines, the exchange of pharmacovigilance data, 
and communication between health professionals [1].  
INN prescribing supports prescribers and pharmacists in their choice of treatment and offers an opportunity for 
physicians to focus on diagnosis and therapy, and for pharmacists to focus on the best choice of medicinal 
product package, together with the patient. INN prescribing should take into account the type of treatment 
(acute or chronic), the medicinal product (e.g. narrow therapeutic index drugs) and the patient (e.g. age, disease, 
medication adherence) [2].  
The concept of INN prescribing is widely adopted by European countries as an implemented health policy [7,8], 
which is sometimes used in combination with (generic) substitution to reduce pharmaceutical expenditures [7,9]. 
In Belgium, INN prescribing is prescribing medicinal products using the name of the active ingredient, the 
corresponding strength, method of administration (e.g. oral, injection, transdermal), the daily dose and duration 
of treatment in weeks and/or days. The duration of treatment is limited to 92 days (3 months) for reimbursable 
medicinal product packages [10]. 
INN prescribing was legally introduced in 2001 in Belgium and became practically possible in 2005 [10]. It was 
presented as an alternative way of prescribing, next to brand name and generic prescribing, to enhance rational 
prescribing. INN prescribing helps patients to minimize their out-of-pocket expenditures. INN prescribing and 
(generic) medication substitution are often related policies [7], but not in Belgium, where medication 
substitution is not allowed [11]. The Belgian medicines agency (the Federal Agency for Medicines and Health 
Products (FAMHP) [12]) established an exhaustive list of products for which treatment should be continued with 
the same product from the same manufacturer, once treatment has started.  This list is called the ‘NO SWITCH’ 
list and includes narrow therapeutic index drugs (NTIDs). An additional smaller list was established with products 
exempted from INN prescribing [13]. 
Parallel to the introduction of INN prescribing in Belgium, two other important containment policies for 
pharmaceutical expenditures were introduced. First, there was the reference price system which implies that 
the reimbursement price is set at 69 % of the current originator reimbursement price, at the moment the patent 
of an original medicinal product expires and generics enter the market. Consequently, patients have to pay a 
‘reference supplement’ when receiving an originator priced above the reference reimbursement price [14,15]. 
Second, a quota for ‘prescribing cheap medicines’ was introduced. The quota, applicable to physicians and 
dentists, refers to a minimum percentage of ‘cheap medicines’ that has to be prescribed each year. ‘Prescribing 
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cheap medicines’ is defined as (1) prescribing originator products with a reduced price, similar to the price of the 
generics, (2) prescribing generics (which, by definition, must be cheaper than the originator under patent) or (3) 
INN prescribing (regardless the type of medicinal product dispensed) [16]. 
When the global financial crisis affected Belgium, austerity measures were introduced to contain pharmaceutical 
expenditures. Two of these measures involved INN prescribing and came into force in April and May 2012 [11].  
The first measure implies that the pharmacist is obliged to respond to an INN prescription by dispensing one of 
the three cheapest medicinal products available. The list of cheapest medicinal products available is updated 
each month.   
The second austerity measure implies that all prescriptions for acute treatment with antibiotics or antifungal 
agents have to be considered as INN prescriptions. This means that the pharmacist is obliged to dispense a 
medicinal product package from the group of cheapest medicinal products, as described above. This is applicable 
to both brand name and generic prescriptions. A procedure of therapeutic objection from the prescriber towards 
medication switch is foreseen for exceptional cases [17,18].  
The introduction of these new austerity measures required a change in the mindset and practices of prescribers, 
pharmacists and patients. It caused commotion and dissatisfaction and was associated with quite some media 
interest [19–25].  
The aim of this study was to explore the attitude of general practitioners (GPs) and pharmacists in Flanders, the 
Dutch-speaking region of Belgium, regarding the current concept of INN prescribing introduced in response to 
the austerity measures of spring 2012.    
2.2. METHODS 
2.2.1. THE QUESTIONNAIRE 
A questionnaire was designed to explore the attitudes of health care professionals and students with regard to 
INN prescribing, as no tool was available.  
The target populations were Flemish general practitioners (GPs) and pharmacists working in public pharmacies.  
Prior to drafting the questionnaire for GPs, a preliminary literature search was performed in PubMed with MeSH 
and search terms: “INN prescribing”; "Attitude of Health Personnel"[Mesh]; “generic prescribing”; "Drug 
Substitution"[Mesh]. Items to be surveyed were extracted from the four relevant articles [2,26–28], including a 
questionnaire performed in French health professionals from Biga et al. in 2005 [27]. An expert meeting, 
including GPs, pharmacists and clinical pharmacologists was organized to identify topics to be questioned. A draft 
questionnaire was developed and tested with the assistance of GPs and pharmacists. Based on the collected 
remarks, the draft questionnaire was adjusted and finalized.  
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In the first part of the questionnaire, demographic characteristics (gender, age, postal code, university affiliation) 
were asked. The questionnaires also assessed location (rural, urban or mixed rural-urban area), social class of 
neighborhood (deprived, residential or social-mixed) and type of general practice (solo, duo, group practice or 
district health centre) or pharmacy (retail pharmacy, cooperative pharmacy or health service pharmacy).  
Next were 391 five-point Likert scale statements (strongly agree/agree/neutral/disagree/strongly disagree) 
classified in four themes: (1) motives for the introduction of policies concerning INN prescribing, (2) attitudes 
towards INN prescribing and the introduced policies, (3) benefits of INN prescribing and (4) drawbacks of INN 
prescribing. Some statements were negated to avoid leading bias.  
The questionnaire ended with an open question where participants could write their own opinion concerning 
the (current) concept of INN prescribing in Belgium.  
The questionnaire was first designed for GPs and then slightly adapted for the pharmacists. All questionnaires 
were made electronically accessible using an online survey tool (eSurvey Creator®) [29].  
2.2.2. SELECTION OF THE SURVEY POPULATION 
A different recruitment strategy for both population groups was applied in the period of February to July 2013.  
For the GPs, the representatives of all local peer review groups (Lokale OnderzoeksKring (LOK)) in Flanders were 
contacted by the scientific association of Flemish GPs (Domus Medica) with the request to circulate the electronic 
link to the questionnaire via e-mail to the members of their review group. One week later, the representatives 
also received a letter by mail with the same request. An announcement was also made twice in the newsletter 
of the scientific association.  
For pharmacists, the seven main professional associations in Flanders were contacted with the request to 
circulate the electronic link to the questionnaire. Most attached the link to their newsletter, one to three times.  
2.2.3. STATISTICS 
Descriptive statistics were performed on the demographic characteristics. Representativity of both subgroups 
was analyzed, based on population data for active GPs and pharmacists from the Health Insurance Institute 
(RijksInstituut voor Ziekte en InvaliditeitVerzekering (RIZIV/INAMI) [30]). 
Further, to present the answers for all statements, the percentage of participants agreeing (i.e. those who 
answered ‘agree’ and ‘strongly agree’) with each statement, was calculated for the entire survey sample and per 
subgroup.  
For each participant, the sum score for all statements pertaining to the third theme ‘benefits of INN prescribing’ 
(called ‘benefits’ hereafter; 13 statements; possible score range 13-65) and the sum score for all statements 
pertaining to the fourth theme ‘drawbacks of INN prescribing’ (called ‘drawbacks’ hereafter; 8 statements; 
                                                                
1 Only 37 in the questionnaire for pharmacists, as two statements were not applicable for pharmacists. 
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possible score range 8-40) was calculated. Some of the statements, formulated in the opposite direction, were 
recoded to align the values of the sum scores correctly.  
The impact of demographic characteristics on the attitude towards INN prescribing was investigated with a 
multiple linear regression model with the sum score for ‘benefits’ and ‘drawbacks’ as a dependent variable.  
All statistical analyses were performed using SPSS® (version 20) with the 0.05 significance level.  
All answers to the open question were transcribed for qualitative analysis. After reading all the comments, a 
coding frame was constructed by two independent coders. Reoccurring topics in these comments were identified 
and categorized in themes. Each comment was applied to the appropriate topic. The results of both coders were 
collated in consensus.  
2.2.4. ETHICAL CONSIDERATIONS 
The survey was approved per sub group by the ethics committee of the Ghent University Hospital (registration 
numbers B670201316270 and B670201316272). For informed consent, the questionnaire started with an 
introduction stating the goal of the survey, explaining that all information received would be handled 
confidentially and that participants could withdraw from the survey at any time. Each participant had to give 
consent before starting the questionnaire by ticking an electronic box “I agree to participate in this study on a 
voluntarily basis”.  
2.3. RESULTS 
In total, 745 completed questionnaires were received (overall response 4.2 %). 522 of them were filled in by 
general practitioners (GPs) (response rate 5.2 %) and 223 by community pharmacists (response rate 2.9 %).  
2.3.1. DEMOGRAPHIC CHARACTERISTICS AND REPRESENTATIVITY OF THE SURVEY SAMPLE 
Details on the demographic characteristic are given in Table 2.1. GPs had a mean age of 48 years and almost 40 
% of them were women. Most of the GPs worked in an urban general practice and the majority of the general 
practices was located in a social-mixed neighborhood. The largest part of the GPs had a solo practice, one-fifth 
worked in a duo-practice, and the others in a group practice, including district health centers. The mean age of 
the pharmacists was 43 years and over half of them were women. The pharmacists were almost equally divided 
over rural, urban and mixed rural-urban areas. The majority of the pharmacies was located in a social-mixed 
neighborhood and most pharmacists worked in a retail pharmacy.  
Based on gender, the survey sample reflected the total population of the GPs, however GPs in the survey sample 
were younger than those in the total population. For pharmacists, the study population was representative for 
mean age, although male pharmacists were overrepresented (Table 2.1).  
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Table 2.1. Demographic characteristics and representativity (for mean age and gender) of the survey sample 
 General practitioners 
N = 522 
Pharmacists 
N = 223 
Total population 9.977 7.708 
% of the total population 5.2 % 2.9 % 
Mean age (range) Total population 51 years 44 years 
Survey sample 
47.7 years  
(23 – 88) 
43.0 years  
(23 – 77) 
Gender (% women) Total population 40.6 73.6 
Survey sample 39.5 56.1 
Location of general practice/pharmacy: 
- Rural 
- Urban 
- Mixed rural-urban 
 
33.4 % 
35.7 % 
30.9 % 
 
39.6 % 
30.9 % 
29.5 % 
Social class of neighbourhood around general 
practice/pharmacy: 
- Poorer 
- Residential 
- Mixed (poorer-residential) 
 
 
13.6 % 
9.5 % 
76.9 % 
 
 
14.4 % 
6.9 % 
78.7 % 
Type of general practice: 
- Solo practice 
- Duo practice 
- Group practice (including district health centers) 
 
40.6 % 
21.0 % 
38.4 % 
Not applicable 
Type of pharmacy: 
- Retail pharmacy 
- Cooperative pharmacy 
- Health service pharmacy 
Not applicable 
 
84.9 % 
12.8 % 
2.3 % 
 
2.3.2. RESPONSES TO THE STATEMENTS 
Details on the responses to the statements are given in Table 2.2. With regard to the motives of health policy 
makers to introduce INN prescribing, the majority of the participants agreed that it was introduced to reduce 
expenditures for the government (88 %) and the patient (57 %).  
Most participants agreed that INN prescribing is acceptable for elderly (57 %), while 90 % disagreed with the 
statement that it is unacceptable for children. However, participants (88 %) stressed that in case of chronic 
treatment, continuity of treatment should be guaranteed.  
The majority of pharmacists (75 %) and a minority of GPs (30 %) agreed that dispensing the cheapest medicinal 
product is only acceptable for acute treatment. For chronic treatment, dispensing the cheapest medicinal 
product was agreed by only 29 % of the pharmacists, while 44 % of the GPs agreed.  
The majority of the participants did not agree that INN prescribing should not be allowed because the clinical 
outcomes between brands and generics differ too much (only 16 % agreed).  
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Table 2.2. Percentage of participants agreeing (agree + strongly agree) per statement for the overall survey 
sample and per subgroup 
Statements % agree (agree + strongly agree) 
 Total 
survey 
sample 
N = 745 
General 
practitioners 
N = 522 
Pharmacists 
N = 223 
% % % 
1. Motives for the introduction of policies concerning INN prescribing 
• To reduce pharmaceutical expenditures (health 
insurance institute) 87.6 85.5 89.7 
• To make medicinal products cheaper for the patient 57.1 61.9 52.3 
• To contribute to rational prescribing* 30.0 29.1 30.9 
• To increase the role of the pharmacist as caregiver 20.8 31.8 9.8 
• To optimize stock management in the pharmacy 14.8 25.4 4.1 
2. Attitudes towards policies introduced concerning (INN) prescribing 
• ‘In case of chronic treatment, it is important to always 
dispense the same medicinal product’ 87.7 83.1 92.3 
• ‘Currently, cost savings are the only aim of INN 
prescribing’ 74.8 64.1 85.5 
• ‘Currently, there is too much emphasis on cost savings 
through INN prescribing’ 67.1 57.2 77.0 
• ‘Prescribing medicines for older people by INN is 
acceptable’  56.9 52.0 61.8 
• ‘At university, only INN prescribing should be taught’ 53.5 33.1 40.8 
• ‘Mandatory dispensing of one of the cheapest 
medicines with an INN prescription is only acceptable 
for acute treatment’  
52.4 29.7 75.0 
• ‘The current way of applying INN prescribing is good’ 43.7 42.4 44.9 
• ‘With INN prescribing, it is important that the 
prescriber receives information on the dispensed 
medicinal product package’ 
36.8 27.3 46.3 
• ‘Mandatory dispensing of one of the cheapest 
medicines with an INN prescription is acceptable for 
chronic treatment’ 
36.7 44.2 29.2 
• ‘Patients are mature enough to choose together with 
the pharmacist the most suitable medicinal product 
package’  
33.0 18.3 47.6 
• ‘Potential cost savings through INN prescribing are 
negated by the additional costs when complications 
occur due to INN prescribing’  
29.0 19.7 38.3 
• ‘The clinical differences between the different brands 
are too large to allow INN prescribing’  16.2 15.6 16.7 
• ‘Prescribing medicinal product for children by INN is 
unacceptable’  10.4 14.7 6.0 
3. Benefits of INN prescribing 
• Patients do not have to pay a reference supplement 66.4 64.9 67.9 
• With one INN prescription, multiple small packages 
can be prescribed/dispensed 63.1 43.7 82.4 
• Contributes significantly to cost savings 56.3 54.4 58.2 
• Patients can receive their medicines quicker in the 
pharmacy 55.4 46.3 64.4 
• Contributes to rational prescribing 43.0 48.7 37.2 
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• Provides more rational stock management in the 
pharmacy 41.5 37.7 45.3 
• Increases the role of pharmacists as caregivers*  40.4 22.0 58.8 
• Shields from marketing influences 38.0 55.6 20.3 
• The physician and pharmacist are more aware of the 
active ingredient*  32.9 44.3 21.5 
• Patients are more aware of the active ingredient in 
the pharmacy 31.2 28.8 33.5 
• Decreases the amount of prescribing errors 23.3 18.2 28.3 
• Reduces the chance of dispensing errors 18.4 15.9 20.8 
• Improves medication adherence 9.0 3.8 14.2 
4. Drawbacks of INN prescribing 
• Increases patient confusion 74.5 81.0 67.9 
• Increases liability of pharmacists* 55.3 50.8 59.8 
• Decreases medication adherence 55.4 42.8 67.9 
• Compromises continuity of treatment* 45.2 49.3 41.1 
• Leads to more administration in the pharmacy*  44.0 27.4 60.6 
• Restricts flexibility of choice (only one of the cheapest 
can be dispensed)  34.6 29.7 39.5 
• Restricts free choice of therapy* 31.6 31.6 ‡ 
• Consultation takes longer 15.6 15.6 ‡ 
*Statements, formulated in the opposite way, were recoded to align the values correctly 
‡These statements were not present in the questionnaire for pharmacists, as they were not relevant for this subgroup 
With regard to the benefits of INN prescribing, few participants agreed that INN prescribing improves medication 
adherence (only 9 %) or that it can decrease prescribing and dispensing errors (only 24 % and 18 % agreed, 
respectively). Two-thirds of all participants agreed that one of the benefits of INN prescribing is the guarantee 
that patients do not have to pay a reference supplement.  
Pharmacists indicated that INN prescribing has the potential to increase the pharmacist’s role as caregiver (59 % 
agreed) and to rationalize stock management (45 % agreed).  
With regard to the drawbacks of INN prescribing, most participants agreed that the current practice of INN 
prescribing causes patient confusion (76 %).  
Pharmacists (61 % agreed) indicated that the current concept of INN prescribing increases the work load in the 
pharmacy. Most GPs did not perceive that INN prescribing extends the duration of the consultation (only 10 % 
agreed).  
2.3.3. SUM SCORES FOR ‘BENEFITS’ AND ‘DRAWBACKS’ 
Calculating the sum score for ‘benefits’ resulted in a mean score of 41.3 for GPs and 42.8 for pharmacists. The 
mean sum score for ‘drawbacks’ was 21.4 for GPs and 22.2 for pharmacists.  
The univariate analysis only revealed an association between demographic characteristics and the sum scores 
for ‘benefits’ and ‘drawbacks’ among GPs, and not among pharmacists.  
The univariate analyses showed that being a younger GP, not allowing visits from (pharmaceutical) company 
representatives, working in a group practice, in a poorer neighborhood, in an urban area, having studied at the 
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Ghent University and being female was associated with the highest sum score for ‘benefits’. In contrast, being 
visited by company representatives, having a solo practice in a social-mixed neighborhood and being an older GP 
was associated with the highest sum score for ‘drawbacks’ (Table 2.3).  
Table 2.3. Results of the univariate and multivariate analysis of the influence of demographic characteristics 
on the sum score for ‘benefits’ and ‘drawbacks’ for general practitioners 
 ‘Benefits’ for GPs 
Univariate Multivariate 
r p-value B Bèta p-value Cumulative R² 
Age -0.244 < 0.001 -0.105 -0.180 < 0.001 0.058 
No visits from (pharmaceutical) 
company representatives 0.236 < 0.001 2.942 0.145 0.001 0.099 
Group practice (including district 
health centers) 0.222 < 0.001 1.716 0.109 0.019 0.107 
General practice in a poorer 
 neighborhood 0.166 < 0.001 2.168 0.097 0.024 0.115 
General practice in an urban area 0.145 0.001 - - - - 
Studied at Ghent University 0.145 0.001 2.235 0.133 0.001 0.131 
Female 0.116 0.008 - - - - 
 
 ‘Drawbacks’ for GPs 
Univariate Multivariate 
r p-value B Bèta p-value Cumulative R² 
Visits from (pharmaceutical) 
company representatives 0.315 < 0.001 3.249 0.287 < 0.001 0.097 
Solo practice 0.182 < 0.001 0.931 0.105 0.015 0.106 
Age 0.138 0.002 - - - - 
General practice in a social-mixed 
neighborhood 0.137 0.002 - - - - 
General practice in a rural area 0.096 0.028 - - - - 
Multivariate analysis revealed a higher sum score for ‘benefits’ (r = -0.180) was most associated with being 
younger and that a higher sum score for ‘drawbacks’ was most associated with being visited by company 
representatives (r = 0.287). Thirteen percent of the variance in the model for ‘benefits’ could be explained by 
age, no visits from company representatives, working in a group practice in a poorer neighborhood and having 
studied at the Ghent University. In the model for ‘drawbacks’, 10 % of the variance could be explained by visit 
from company representatives and having a solo practice (Table 2.3).  
2.3.4. PERSONAL OPINIONS  
Almost half of the participating GPs (44.8 %) and pharmacists (42.6 %) gave their opinion regarding the concept 
of INN prescribing at the end of the questionnaire (Box 2.1).  
The comments revealed four different themes, covering different topics. The first theme was “The current 
concept of INN prescribing does not guarantee the continuity of treatment”. The second was “Medical software 
is not adapted for proper INN prescribing and communication between GPs and pharmacists” and the third 
theme “Communication problems between GPs and pharmacists”. The fourth theme “Practical implications of 
the new policies for pharmacists” was only applicable for pharmacists (Box 2.1).  
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Box 2.1. Themes and topics commented on the open question 
Theme 1: 
“The current concept of International Nonproprietary Name (INN) prescribing does not guarantee the 
continuity of treatment” - Applicable for general practitioners (GPs) and pharmacists 
• Patient confusion 
GP, ♀, 43 years: 
“INN prescribing causes major patient confusion”  
 
Pharmacist, ♂, 59 years: 
“INN prescribing is most confusing for older patients”   
• Medication adherence  
GP, ♀, 49 years: 
“I like to prescribe by INN, but my patients should always receive a 
product from the same manufacturer”  
 
Pharmacist, ♂, 53 years: 
“Continuously switching between brands for chronic medication 
compromises medication adherence”  
• Current way of naming generics 
(active ingredient + name of 
generic company 
GP, ♂, 46 years: 
“It might be better to put the INN in large print on the medicinal 
package, and to standardize the packages”  
 
Pharmacist, ♂, 53 years: 
“The generic company name should not be part of the medicinal 
product name; this causes confusion”  
• Preference to prescribe ‘cheap 
medicines’ instead of by INN 
GP, ♂, 47 years: 
“As continuity of treatment is very important, I am in favor of 
prescribing cheap medicines instead of by INN”  
 
Pharmacist, ♀, 60 years: 
“Physicians rarely prescribe by INN, usually they prescribe 
generics”  
• Concerns about patients with 
chronic treatment 
GP, ♀, 36 years: 
“The main disadvantage of INN prescribing are the problems that 
can occur in case of chronic treatment”  
 
Pharmacist, ♀, 60 years: 
“In case of chronic treatment, continuity of treatment supercedes 
limited cost savings”  
• Medication errors 
GP, ♂, 29 years: 
“Due to frequent switching, it might occur that some of my 
patients take two pills of the same product (e.g. Bisoprolol Sandoz® 
and Bisoprolol Mylan®)”  
• Continuity of treatment 
GP, ♂, 56 years: 
“INN prescribing does not guarantee the continuity of treatment. 
This is the main issue.”  
 
Pharmacist, ♂, 34 years: 
“In case of INN prescribing during chronic treatment, the continuity 
of treatment should prevail”  
• Dissatisfaction on policies 
pushed by the government 
GP, ♂, 48 years: 
“Mandatory regulation is usually not welcomed. I don’t understand 
the added value of the current concept of INN prescribing”  
 
 
GP, ♂, 52 years: 
“Why do GPs have to solve the budgetary problems?”   
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Theme 2: 
“Software is not adapted for proper INN prescribing and communication between GPs and community 
pharmacists” - Applicable for general practitioners and pharmacists 
• Inability of medical software to 
easily make an INN prescription 
and register it properly  
GP, ♀, 32 years: 
“Unfortunately I cannot prescribe by INN with my prescription 
software”  
 
Pharmacist, ♂, 47 years: 
“Apparently, GPs prescription software does not permit INN 
prescribing”  
• Feedback on the dispensed 
medical product package 
GP, ♀, 33 years: 
“It would be convenient to know which medicinal product package 
is dispensed”  
 
Pharmacist, ♂, 47 years: 
“It should be possible with pharmacy software to automatically 
inform the prescriber on the dispensed medicinal product package”  
Theme 3: 
“Communication problems and mutual incomprehension between GPs and pharmacists” - 
Applicable for general practitioners (and pharmacists) 
• Decisions made by 
GPs/pharmacists when 
making/dispensing prescriptions  
GP, ♂, 62 years: 
“In reality, pharmacists do not always dispense the cheapest 
available, but those which are most profitable for them”  
 
Pharmacist, ♂, 47 years: 
“It should be made clear to physicians that INN prescribing ensures 
patients receiving the cheapest product available. Physicians 
distrust pharmacists.”  
• Pharmacists put profits ahead of 
patient care 
GP, ♀, 44 years: 
“It appears to me that having one of the cheapest products 
dispensed with INN prescribing is the same as the most beneficial 
product for the pharmacist”  
 
GP, ♂, 50 years: 
Currently, INN prescribing is only advantageous for the pharmacist. 
Due to the current concept, pharmacists also substitute other 
medicinal product besides antibiotics and antifungal treatment”  
• Fee for pharmacists 
GP, ♂, 52 years: 
“I do not understand why pharmacists receive an additional fee 
when dispensing an INN prescription”  
 
GP, ♂, 34 years: 
“I do not get why pharmacists get rewarded for the efforts we 
make” 
• Increase of the liability of 
pharmacists 
GP, ♂, 56 years: 
“Maintaining the continuity of treatment and preventing errors 
with INN prescriptions is the responsibility of the pharmacist”  
 
GP, ♂, 45 years: 
“The liability of the pharmacist should be increased”  
Theme 4: 
“The practical implications of the new policies for the pharmacists” - 
Applicable for pharmacists 
• Stock management 
Pharmacist, ♀, 43 years: 
“These policies make stock management almost impossible”  
 
Pharmacist, ♂, 55 years: 
“This hinders any sort of stock management”  
Chapter 2 
66 
 
• Work load 
 
Pharmacist, ♂, 44 years: 
“INN prescriptions require more explanation to motivate patients, 
especially the elderly”  
 
Pharmacist, ♀, 58 years: 
“INN prescribing is good, but it implies a higher work load for us”  
• Financial detriment 
Pharmacist, ♀, 30 years: 
“Financial detriments for pharmacists are due to massive price 
cuts”  
 
Pharmacist, ♀ , 42 years: 
“INN prescribing created a negative price spiral resulting in a 
significant decline in turnover in our pharmacy”  
 
2.4. DISCUSSION 
To the best of our knowledge, this survey was the first to jointly explore the opinions of general practitioners 
(GPs) and pharmacists on INN prescribing after a major policy change.  
2.4.1. MAIN FINDINGS 
This survey showed that participants perceived that INN prescribing was introduced to reduce the 
pharmaceutical expenditures of the government and the out-of-pocket fees for the patients. Our results 
demonstrated that most agreed that INN prescribing has its potential to be widely used a way of rational 
prescribing. However, all participants stressed the importance of continuity of treatment, especially in the (older) 
chronic patient, and the danger for patient confusion due the new policy. 
Comments in response to the open question revealed communication problems and mutual incomprehension 
between GPs and pharmacists, although both are willing to contribute to rational medication use, including INN 
prescribing. Many GPs also stated that electronic INN prescribing and the correct registration of an INN 
prescription is currently not possible.  
The multivariate analysis showed that mainly younger GPs working in a group practice, situated in a poorer area, 
recognized the (potential) benefits of INN prescribing. This is in contrast to the stronger perception of drawbacks 
by older GPs with a solo practice, receiving visits from (pharmaceutical) company representatives.  
2.4.2. COMPARISON WITH PREVIOUS RESEARCH 
In 2005, comparable research was performed by Biga et al. in a  region in France, investigating the perception on 
INN prescribing of GPs, pharmacists and patients [27]. Although the French health care system (and the specific 
regulation on INN prescribing) differs from the Belgian system, the survey showed that INN prescribing was 
generally well accepted. However, GPs seemed more reluctant towards INN prescribing than pharmacists and 
patients.  
In Belgium, similar research investigated the attitudes of GPs and pharmacists towards INN prescribing in general 
[31]; however, this study took place before the introduction of the new policies (winter 2011-2012). This survey 
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demonstrated an already existing negative attitude towards INN prescribing. Our results confirmed that this 
perception further deteriorated after the policy change in 2012.  
2.4.3. STRENGTHS & LIMITATIONS 
The first strength of this survey was the structured exploration of the opinion of GPs and pharmacists. Since the 
policy changes were associated with quite some commotion and dissatisfaction, the opinion of (future) primary 
caregivers is valuable.  
The second strength was the opportunity for participants to give their own opinion with regard to INN prescribing 
and its related aspects in an open question. The survey was administered between February and July 2013, 
almost one year after the introduction of the new policy. This provided adequate time for GPs and pharmacists 
to explore and evaluate its implications.  
Our survey sample was acceptable, especially when taking into account the representativity of the sample for all 
subgroups, although the GPs in our survey sample were, on average, three years younger than those in the 
eligible population. This can be explained by the fact younger participants may be more computer savvy and 
might be more prone to answer an electronic survey. We have no explanation for the slight overrepresentation 
of male pharmacists. It is possible that selection bias may have resulted from explicit opponents and proponents 
of INN prescribing choosing to participate, as they might have considered this survey as an opportunity to express 
their views on the subject. The frequency and depth of comments left at the end of this questionnaire is a 
testament of the interest in this subject. 
Although our questionnaire was self-designed, it was based on literature, expert consultation and pilot testing. 
An ex-post evaluation showed that a limited number of statements could have been formulated more clearly. 
However, an analysis of the topics in the open question revealed that only the limited possibilities of medical 
software with regard to INN prescribing was not questioned through a statement.  
Another limitation is that we only addressed GPs and pharmacists in the Flanders region of Belgium. Our results 
cannot be extrapolated to GPs and pharmacists in Wallonia, the French-speaking part of Belgium. 
2.4.4. IMPLICATIONS FOR PRACTICE 
Our results emphasized the importance of consistent treatment, especially in chronic (older) patients. GPs and 
pharmacists expressed their concern that the new policies may confuse patients due to the possibly that the 
lowest cost medicinal products will change monthly, resulting in frequent switching that could lead to 
nonadherence and erroneous drug use by patients. These concerns were probably founded as literature showed 
that differences in medicinal product name, packaging and physical attributes negatively influence medication 
adherence and result in medication errors, due to patient confusion and discontent [32–38]. Studies also 
confirmed that good communication with patients is essential when medication switches occur [39–41].  
This survey also showed that medical software and electronic patient records (EPR) need to be adapted for 
physicians to easily make and correctly register INN prescriptions. Initiatives were already taken by the Belgian 
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government to implement INN prescribing in electronic prescribing and register INN prescriptions using a unique 
identification number [13]. Additionally, GPs reported the need for (detailed) information on the dispensed 
medicinal product package when prescribed by INN. Therefore, it should be possible for GPs to receive 
information from the pharmacist on the dispensed medicinal product package through the e-health platform and 
medical software [22]. 
One of the major comments of pharmacists was that monthly changing lists of the cheapest medicines does not 
facilitate rational stock management. This monthly update also results in the possibility of chronic patients 
receiving a medicinal product of a different manufacturer every month, which can lead to patient confusion and 
nonadherence, as discussed above. Therefore, we suggest a quarterly or biannual update of those lists. 
The answers on the open question revealed communication problems between GPs and pharmacists, including 
the shift of liability from GPs to pharmacists and additional fees related to INN prescribing. Structured initiatives 
to improve the relationship and reciprocal understanding between both should be taken, by the government or 
by professional associations [42,43].  
2.5. CONCLUSION 
This study revealed that GPs and pharmacists consider the core concept of INN prescribing, i.e. using the name 
of the active ingredient(s) to identify the medicinal product and having a cheap one dispensed, as a major 
strength, offering many possibilities for rational drug prescribing. However, the current way in which INN 
prescribing is applied in Belgium leads to many concerns in primary health professionals with regard to patient 
confusion and medication adherence. Slightly adapting the current concept of INN prescribing to these concerns 
can turn INN prescribing into one of the major policies in Belgium reducing pharmaceutical expenditures and can 
stimulate rational drug prescribing.  
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ABSTRACT 
Objective. The aim was to investigate the attitudes of Dutch-speaking medicine students and pharmacy students 
towards International Nonproprietary Name (INN) prescribing. INN prescribing is using the name of the active 
ingredient for prescribing and started in 2005 in Belgium. It underwent major policy change in spring 2012.  
Methods. An electronic questionnaire with 39 five-point Likert scale statements was administered in 2013. It was 
circulated via the electronic platform of all four Dutch-speaking universities in Belgium. Descriptive statistics 
were performed on the collected demographic characteristics and representativity of the survey sample was 
analyzed. Differences in attitudes between medicine students and pharmacies students were tested with a Chi²-
test.  
Results. We received 487 valid responses with representative samples for both groups of students, with regard 
to gender and age. The response rate was almost 20 % for medicine students and 46 % for pharmacy students. 
Although over 75 % of the students stressed the importance of a guaranteed continuity of treatment, 72 % 
accepted the current way INN prescribing is applied in Belgium. Despite this acceptance, students did not want 
INN prescribing being exclusively taught during training.  
Conclusion. Students believe that the concept of INN prescribing has the potential to contribute to rational drug 
prescribing and utilization, provided that continuity of treatment can be guaranteed. Students wish that INN 
prescribing is more prominently, but not exclusively, taught at university. All this favors the rational 
implementation of INN prescribing in education and clinical practice. 
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3.1. INTRODUCTION 
INN prescribing is using the active ingredient name(s), instead of the brand name or branded generic name, to 
identify the medicinal product. Using the INN for prescribing can contribute to rational drug prescribing and 
utilization. In addition, INN prescribing can also be implemented as a cost-containment policy, sometimes in 
combination or related to (generic) substitution [1]. At university, medicine and pharmacy students can learn 
about different types of prescribing: brand name prescribing, prescribing of branded generics and International 
Nonproprietary Name (INN) prescribing.  
Since 2001, INN prescribing is legally allowed in Belgium. Initially, it was introduced to enhance rational drug 
utilization [2], but was turned into a cost-containment measure when the global financial crisis also affected 
Belgium. Firstly, starting from April 2012, the pharmacist is obliged to dispense one of the three cheapest 
medicinal products available when prescribed by INN. The list of cheapest products available is updated monthly. 
Secondly, starting from May 2012, when receiving a prescription for acute treatment with antibiotics or 
antifungal agents, the pharmacist is obliged to treat this as it was an INN prescribing and hence dispense one of 
the three cheapest medicinal products. This measure is applicable for brand name and branded generic name 
prescriptions [3,4].  
The introduction of these two cost-containment measures was extensively criticized and received quite some 
attention from the (professional) media [5–10].  
This study is part of a broader research which also investigated the attitudes of general practitioners (GPs) and 
pharmacists and is presented elsewhere [11]. The aim of this study is to explore the attitudes of medicine 
students and pharmacy students from the four Dutch-speaking universities in Belgium, regarding the concept of 
INN prescribing and the austerity measures of spring 2012 in Belgium. As these students are future prescribers 
and pharmacists, it is important to also know about their attitudes and opinions on INN prescribing for the 
successful implementation of this concept in education and clinical practice.  
3.2. METHODS 
3.2.1. DEVELOPMENT AND CIRCULATION OF THE QUESTIONNAIRE 
A self-designed questionnaire was circulated to explore the attitudes of medicine students (3rd and 4th Master) 
and pharmacy students (2nd Master) with regard to INN prescribing.  
The questionnaire started with questions on demographic characteristics (gender, age, postal code and 
university), followed by 39 five-point Likert scale statements (strongly agree/agree/neutral/disagree/strongly 
disagree) covering four themes: (1) motives for the introduction of policies concerning INN prescribing, (2) the 
attitude towards INN prescribing and the introduced policies, (3) benefits of INN prescribing and (4) drawbacks 
of INN prescribing. Some statements were negated to avoid leading bias.  
Further details on the development of the questionnaire were presented elsewhere [11]. 
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All questionnaires were made electronically accessible using an online survey tool (eSurvey Creator®) [12]. 
Between February and May 2013, the link to the questionnaire was circulated via the electronic platform of all 
four Dutch-speaking universities with a medical and pharmaceutical department. Two reminders were sent after 
the initial announcement. 
3.2.2. STATISTICS 
Descriptive statistics were performed on the demographic characteristics. Representativity of the survey sample 
was analyzed for gender and university. To present the answers for all statements, the percentage of students 
agreeing (i.e. those who answered ‘agree’ and ‘strongly agree’) with each statement, was calculated.  
To test for differences in opinions between medicine students and pharmacy students, and for differences 
between the universities, a Chi²-test was performed.  
All statistical analyses where performed using SPSS® (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, 
Version 20.0. Armonk, NY: IBM Corp.) with the 0.05 significance level.  
3.2.3. ETHICAL CONSIDERATIONS 
The survey was approved by the ethics committee of the Ghent University Hospital (registration number 
B670201316273). For informed consent, the questionnaire started with an introduction stating the goal of the 
survey, explaining that all received information would be handled confidentially and that students could 
withdraw from the survey at any time. Each student had to give consent before starting the questionnaire by 
ticking an electronic box “I agree to participate in this study on a voluntarily basis”.  
3.3. RESULTS 
In total, 487 completed questionnaires were received, of which 295 by medicine students (response rate 19.8 %) 
and 192 by pharmacy students (response rate 45.7 %) (Table 3.1).   
The mean age for medicine students was 24 years and over 65 % of them were females. For pharmacy students, 
the mean age was 23 years and 75 % of them were females.  There was some underrepresentation of medicine 
students from one university (Table 3.1).  
3.3.1. RESPONSES TO THE STATEMENTS 
Details on the responses to the statements are given in Table 3.2. For medicine students and pharmacy students 
it was clear that INN prescribing was introduced to reduce expenditures for the health insurance (74 % agreed) 
and for the patient (71 % agreed). Although over three-quarters of the students agreed that it is important to 
always have the same medicinal product dispensed during chronic treatment, 72 % mean the current way of 
applying INN prescribing is good. In addition, 63 % agreed that medicines for older people can be prescribed by 
INN.  
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Table 3.1. Demographic characteristics and representativity of the survey sample 
Students perceived as main benefits of INN prescribing that (1) patients do not have to pay an additional out-of-
pocket fee (68 % agreed), (2) INN prescribing shields from marketing influences (67 % agreed) and (3) it 
contributes to cost savings (54 % agreed).  
Students indicated as main drawbacks that INN prescribing increases patient confusion (74 % agreed) and that it 
does not result in improved medication adherence (only 10 % agreed that INN prescribing improves medication 
adherence).  
No differences between the opinions of students from different universities were discovered and the opinions 
of medicine students and pharmacy students did not relevantly differ, for most of the statements. However, 
more pharmacy students (49 %) meant that patients are mature enough to choose the most suitable product, 
together with pharmacist, compared to only 25 % of the medicine students. More medicine students (38 % vs. 
23 % pharmacy students) were convinced that INN prescribing can contribute to rational stock management in 
the pharmacy and more medicine students (57 % vs. 41 % pharmacy students) indicated that the liability of the 
pharmacist increases with an INN prescription.  
Finally, only a minority of the students (29 %) was convinced that INN prescribing should be the only concept to 
be taught.  
 Medicine students Pharmacy students 
 Participants 
Total population 1.491 420 
Survey sample 295 192 
Response rate 19.8 % 45.7 % 
 Age 
Mean age (range) 24 years (21 – 54) 23 years (20 – 35) 
 Gender (% women) 
Total population 61.5 79.0 
Survey sample 65.4 74.9 
 University 
 University 1 
Total population 221 71 
Survey sample 55 18 
Response rate 24.9 % 25.4 % 
 University 2 
Total population 95 38 
Survey sample 25 16 
Response rate 26.3 % 42.1 % 
 University 3 
Total population 406 149 
Survey sample 52 124 
Response rate 12.8 % 83.2 % 
 University 4 
Total population 769 162 
Survey sample 163 34 
Response rate 21.9 % 21.0 % 
With University 1 the University of Antwerp, University 2 the Vrije Universiteit Brussel, University 3 the 
Ghent University and University 4 the KU Leuven.  
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Table 3.2. Percentage of students agreeing (agree + strongly agree) for all statements and per subgroup. 
Results of the Chi²-test for different opinions between both groups of students 
Statements % agree (agree + strongly agree) 
 Total 
survey 
sample 
N = 487 
Medicine 
students 
N = 295 
Pharmacy 
students 
N = 192 
P-value 
Chi²-
test 
% % % 
1. Motives for the introduction of policies concerning INN prescribing 
• To reduce pharmaceutical expenditures (health 
insurance institute) 74.0 74.1 73.9 0.966 
• To make medicinal products cheaper for the 
patient 71.0 71.0 71.0 0.992 
• To contribute to rational prescribing* 18.1 19.0 16.7 0.563 
• To increase the role of the pharmacist as caregiver 18.9 15.5 24.4 0.025 
• To optimize stock management in the pharmacy 10.3 13.2 5.7 0.014 
2. Attitudes towards introduced policies concerning (INN) prescribing 
• ‘In case of chronic treatment, it is important to 
always have the same medicinal product 
dispensed’ 
78.8 73.8 86.3 0.002 
• ‘Currently, cost savings are the only aim of INN 
prescribing’ 41.4 38.1 46.6 0.088 
• ‘Currently, there is too much emphasis on cost 
savings for INN prescribing’ 47.0 38.7 60.3 < 0.001 
• ‘Medicines for older people prescribing by INN is 
acceptable’  63.1 68.1 55.4 0.008 
• ‘At university, only INN prescribing should be 
taught’ 28.5 32.3 22.6 0.031 
• ‘Mandatory dispensing one of the cheapest 
medicines with an INN prescription is only 
acceptable for acute treatment’  
30.7 25.4 38.9 0.003 
• ‘The current way of applying INN prescribing is 
good’ 72.0 80.2 59.5 < 0.001 
• ‘With INN prescribing, it is important that the 
prescriber receives information on the dispensed 
medicinal product package’ 
35.6 33.1 39.7 0.180 
• ‘Mandatory dispensing one of the cheapest 
medicines with an INN prescription is acceptable 
for chronic treatment’ 
56.6 62.9 47.0 0.001 
• ‘Patients are mature enough to choose together 
with the pharmacist the most suitable medicinal 
product package’  
34.7 25.4 49.0 < 0.001 
• ‘Potential cost savings through INN prescribing are 
negated by the additional costs when 
complications occur due to INN prescribing’  
13.4 11.9 15.8 0.268 
• ‘The clinical differences between the different 
brands are too large to allow INN prescribing’  10.6 10.2 11.3 0.706 
• ‘Prescribing medicinal product for children by INN 
is unacceptable’  11.8 12.8 10.2 0.407 
3. Benefits of INN prescribing 
• Patients do not have to pay a reference 
supplement 67.7 72.7 60.0 0.009 
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• With one INN prescription, multiple small 
packages can be prescribed/dispensed 5.4 4.2 7.2 0.195 
• Contributes significantly to cost savings 54.1 55.9 51.3 0.377 
• Patients can receive their medicines quicker in the 
pharmacy 49.6 44.8 57.0 0.020 
• Contributes to rational prescribing 47.5 51.5 41.3 0.052 
• Provides more rational stock management in the 
pharmacy 31.9 37.8 22.7 0.002 
• Increases the role of pharmacists as caregivers*  30.0 28.3 32.7 0.366 
• Shields from marketing influences 67.2 71.0 61.2 0.044 
• The awareness of the active ingredient is bigger 
for physician and pharmacist*  20.5 24.3 14.6 0.021 
• Patients are more aware of the active ingredient 
in the pharmacy 41.1 39.9 43.0 0.542 
• Decreases the amount of prescribing errors 28.8 30.1 26.7 0.463 
• Reduces the chance of dispensing errors 19.3 16.7 23.3 0.111 
• Improves medication adherence 10.0 10.5 9.2 0.668 
4. Drawbacks of INN prescribing 
• Increases patient confusion 73.2 72.3 74.7 0.609 
• Liability of pharmacists increases * 50.7 57.1 40.7 0.002 
• Decreases medication adherence 37.4 35.8 40.0 0.405 
• Compromises continuity of treatment* 37.2 34.2 41.7 0.137 
• Leads to more administration in the pharmacy*  33.3 20.3 53.7 < 0.001 
• Restricts flexibility of choice (only one of the 
cheapest can be dispensed)  28.7 31.2 26.7 0.486 
• Restricts free choice of therapy* 37.4 30.0 47.0 0.002 
• Consultation takes longer 3.6 4.6 2.0 0.172 
*Statements, formulated in the opposite way, were recoded to align the values correctly 
 
3.4. DISCUSSION 
To the best of our knowledge, this survey was the first to explore the opinion of medicine students and pharmacy 
students on INN prescribing.  
A representative sample of students completed the questionnaire, based on gender and mean age. Differences 
in response rate between universities, with an underrepresentation of medicine students from one university, 
are difficult to explain.  
Students accepted the basic concept of INN prescribing, i.e. prescribing by active ingredient name and having a 
cheaper product dispensed, but also stressed the need for continuity of treatment. Some differences between 
the opinions of medicine students and pharmacy students were found for statements related to the pharmacy 
and the role of the pharmacist. No differences between attitudes of students from different universities could 
be found.  
Despite acceptance of the concept, medicine students and pharmacy students do not wish INN prescribing to be 
the only way taught during training. They also indicated that INN prescribing can shield from marketing 
influences, which favors the implementation of INN prescribing in education and clinical practice as early contact 
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of students with pharmaceutical marketing is associated with biased attitudes [13,14]. Our questionnaire did not 
include statements to investigate the students’ opinion on the implementation of an INN prescribing teaching 
module in e-learning. It would have been interesting however to explore this opinion as e-learning plays an 
expanding role in medical education [15]. 
Although students accepted INN prescribing more than general practitioners and pharmacists for chronic 
treatment and for the elderly, the responses to the statements were mostly in line with those of the general 
practitioners and pharmacists [11]. This latter can be the result of students being influenced by or reflecting the 
opinions of their peers (professors at university, training supervisors). However, in contrast to their peers, 
students answered quite some statements with ‘neutral’, showing far less pronounced opinions towards INN 
prescribing. This might indicate that students not had enough practical experience to fully understand the 
implications of the recently introduced policies.  
3.5. CONCLUSION 
Students believe that the concept of INN prescribing has the potential to contribute to rational drug prescribing 
and utilization, provided that continuity of treatment can be guaranteed. Students wish that INN prescribing is 
more prominently, but not exclusively, taught at university. All this favors the rational implementation of INN 
prescribing in education and clinical practice.  
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ABSTRACT 
Objectives. To give an overview of the exemptions related to INN prescribing and generic substitution. To 
compare the most relevant exemptions related to INN prescribing and generic substitution, as these differ widely 
within European countries.  
Methods. A self-designed questionnaire was sent to drug utilization researchers in 21 European countries (BE, 
CZ, DE, DK, EE, ES, FI, FR, HU, HR, IE, IS, IT, LT, NL, NO, PT, SI, SK, SE and UK). Completed questionnaires were 
validated by the researchers and sent to country representatives from competent authorities for a second 
review. 
Results. Sixteen countries (BE, DE, EE, ES, FI, FR, HU, HR, IT, LT, NL, NO, PT, SI, SE and UK) completed the 
questionnaire and all were validated. INN prescribing is allowed in all countries, except in Sweden. Generic 
substitution is allowed in six countries (HR, EE, HU, IT, NL and SI) and mandatory in Finland, France, Germany, 
Norway, Spain and Sweden, but exemptions apply. It is not allowed in Belgium, Lithuania, Portugal and the United 
Kingdom. Twelve countries (BE, DE, ES, FI, FR, HR, LT, NL, NO, PT, SE and UK) have established explicit lists of 
medical products which cannot be prescribed by INN or substituted. These lists differ between countries in terms 
of products included and whether they are binding or advisory. The most common exempted products can be 
categorized in eight different groups of products: anti-arrhythmia agents, antiepileptic agents, biologicals and 
biosimilars, cardiac glycosides, coumarin anticoagulants, immunosuppressive agents, thyroid hormones and 
products used with specific aids (e.g. inhalation medications, insulin pens, …).  
Conclusion. National prescribing regulation differs widely between European countries. In particular the wide 
variability in exemptions related to INN prescribing and generic substitution and the lack of a definition for 
narrow therapeutic index drugs highlight the need for consensus. The results of our study can serve as a basis 
for the competent European authorities to establish a common guideline on this subject.  
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4.1. INTRODUCTION 
Medicines or drugs are single or combined substances for treatment and prevention of diseases [1]. Since long, 
medicines have been subject to specific regulation, as no substance is completely safe and medicines are not 
ordinary consumer products. Medicines regulation covers different pharmaceutical policies, including policies on 
registration, pricing, reimbursement and medicines prescribing, to promote and protect public health. This 
medicines regulation differs between countries in scope and implementation as characteristics on national 
medicines regulation are influenced by underlying attitudes of governments towards providing and financing 
healthcare and by their response to medical and financial crises [2,3]. 
Pharmaceutical policies on medicines prescribing, also referred to as ‘prescribing regulation’, describe the 
applicable rules and practical implementation of the allowed ways of prescribing. The allowed ways of prescribing 
also depend on the available types of medicinal products in each country, which are ‘brands’ and ‘generics’. 
Brands include innovator products, licensed products and “well-established use” products, which are all 
marketed under a fantasy name but differ in the type of file submitted for marketing registration.  For innovators, 
a complete marketing authorization file (including quality data and results of toxicological, pharmacological and 
clinical trials) must be established, while for licensed products and “well-established use” products an abridged 
file can be used [4,5]. We prefer not to use the widespread term ‘copy’ as it refers to a container concept used 
to describe  two different types medicinal products, i.e. licensed products and ‘well-established use’ products.  
Licensed products are those where the marketing authorization license is bought from the innovator company 
by another company before patient expiry. The license is then called a ‘piggy-back’ license [5]. “Well-established 
use” products contain active ingredients which are used within the European Union for at least ten years and for 
which the effect and safety is proven [6]. These products are authorized based on a bibliographic record and 
scientific literature [4]. Generics include branded and unbranded generics, which do not differ in marketing 
registration, but in the way they are named. The branded generic name can be (1) a combination of the active 
ingredient name and generic company name (e.g. Simvastatin Teva®) or (2) a fantasy name given by the generic 
company (e.g. Lipcut® is the Sandoz® generic of simvastatin, available in Finland [7]). Unbranded generics are 
medicinal products where the name on the package does not include the name of the generic company, but is 
only the active ingredient name or the INN, e.g. simvastatin.  
The possible ways of prescribing can be ‘brand name prescribing’, ‘generic prescribing’ and ‘International 
Nonproprietary Name (INN) prescribing’. These ways do not only differ in how medicines are prescribed, but also 
in the type of medicinal products that can be dispensed. Brand name prescribing refers to using the brand name 
for prescribing and having a brand (innovator, licensed product or “well-established use” product) dispensed. 
Generic prescribing includes prescribing of a (branded) generic and INN prescribing, resulting in the dispensing 
of a generic product. INN prescribing however can also result in the dispensing of a brand product. This latter is 
possible when the brand product has the same price as the available generic products or when no generic 
products are available (yet).  
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Using the INN for prescribing was introduced in the mid-eighties in France, by the journal ‘La Revue Prescrire’, to 
contribute to rational and safe drug prescribing and utilization [8]. Although endorsed by the World Health 
Organization (WHO) [9], INN prescribing was never really accepted as a way of prescribing in continental Europe. 
However, since the global financial crisis also affected Europe in 2008, INN prescribing was forced into a cost-
containment measure for pharmaceutical expenditures in many countries [10,11].  
While INN prescribing is a pharmaceutical policy executed by the prescriber, generic substitution is a policy 
performed at the pharmacy level. Generic substitution was introduced to enhance the role of the pharmacist as 
care giver and to promote the use of generics [12].  Generic substitution is when the prescribed medicinal product 
(a brand or branded generic) is substituted in the pharmacy by another medical product (usually a generic 
product) which is bioequivalent. Generic substitution can occur with or without permission of the prescriber.  
Regarding INN prescribing and generic substitution, national prescribing regulation often includes lists of 
medicinal products which can or not be prescribed by INN or products which can or not be substituted. These 
lists differ between countries, but regularly exempt narrow therapeutic index drugs (NTIDs) from INN prescribing 
or generic substitution. However, within the European Union, there is no official definition or established list of 
NTIDs [13,14]. 
Therefore, the first aim of this study was to give an overview of exemptions related to INN prescribing and generic 
substitution. The second aim is to compare the most relevant exemptions, as these differ widely within European 
countries. For the correct understanding and completeness, we start with an overview of the types of medicinal 
products available and the allowed ways of prescribing.  
4.2. METHODS 
4.2.1. QUESTIONNAIRE  
Prior to drafting the questionnaire, a preliminary literature search in PubMed and on the world wide web was 
performed using the European country names and search terms: “Drug Prescriptions/standards” [MeSH], “Drugs, 
generic” [MeSH], “Drug substitution” [MeSH], “Health policy” [MeSH], “health care system”, “prescribing 
regulation”, “medicines regulation”, “reference price system”.  All relevant information was extracted and used 
as framework for the draft questionnaire. The draft questionnaire was discussed and tested in several expert 
meetings including general practitioners, pharmacists, drug utilization researchers and experts in pharmaceutical 
policies. The draft questionnaire was adjusted to the remarks of the experts.  Afterwards, it was tested by a drug 
utilization researcher and finalized according to the remarks.  
For the correct understanding and interpretation of used terms in the questionnaire, a glossary was composed. 
This glossary comprised definitions retrieved from other glossaries and sources (such as the MeSH database, the 
Merriam-Webster dictionary, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) 
and the Pharmaceutical Health Information System Glossary 2009 [15]). When no sufficient definition was found, 
existing definitions were adapted or completed, or when no definition was available, one was established by the 
authors.  
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The questionnaire was divided into five sections, with 51 questions in total. However, some questions are beyond 
the scope of this article and therefore will not be further discussed. The first section contained questions about 
e.g. the types of medicinal products available, whether a reference price system is applied and whether 
electronic prescribing is possible. Section 2 was called “Prescribing by brand name” and contained questions on 
(a) the regulation of this way of prescribing, including whether it is allowed or mandatory to prescribe by brand 
name. Applicable exemptions related to this regulation could also be mentioned. Next were questions on (b) the 
items needed for a correct brand name prescription (e.g. strength, route of administration) and at last questions 
on (c) whether generic substitution is allowed or mandatory with a brand name prescription and which 
exemptions apply. Section 3 was called “Prescribing of branded generics” and section 4 “INN prescribing”. These 
sections were constructed similar to section 2. Section 5 “Education” focused on the way students where taught 
to prescribe at university. After each question and at the end of the questionnaire, space was provided for 
additional remarks.  
4.2.2. CIRCULATING & VALIDATING THE QUESTIONNAIRE 
With the help of the European Drug Utilization Research Group (EuroDURG) [16], drug utilization (DU) 
researchers in 21 European countries were identified and contacted by e-mail in September 2013. The DU 
researchers were asked to complete the questionnaire, within two months if possible. Completed questionnaires 
were returned to the authors and the given answers were validated with information available on websites of 
national health insurance institutes, medicines agencies and professional associations. Afterwards, the 
completed questionnaires were sent to a country representative from competent authorities for a second 
review. These representatives were contacted by the Head of the WHO Collaborating Centre for Pharmaceutical 
Pricing and Reimbursement Policies [17]. Reviewed questionnaires were returned to the authors for analysis.  
4.3. RESULTS 
The questionnaire was sent to 21 countries (BE, CZ, DE, DK, EE, ES, FI, FR, HU, HR, IE, IS, IT, LT, NL, NO, PT, SI, SK, 
SE and UK) of which 5 did not participate (CZ, DK, IE, IS and SK) and the remaining 16 completed the 
questionnaire. All completed questionnaires were validated by the authors and 7 of them were reviewed a 
second time by a representative from the competent authorities (BE, FI, FR, HU, LT, NL and NO) (Table 4.1).  
4.3.1. AVAILABLE TYPES OF MEDICINAL PRODUCTS 
Brands (innovators, licensed products and “well-established use” products) and branded generics were available 
in all 16 countries. Unbranded generics were only available in two countries: the Netherlands and the United 
Kingdom (UK). In the UK, unbranded generics were the most common generics.  
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Table 4.1. Overview of countries contacted, participating and validated 
Countries contacted 
N = 21 
Country name 
abbreviation 
Participated 
in project 
N = 16 
Questionnaire validated 
N = 16 
Questionnaire reviewed 
2nd time 
N = 7 
Belgium BE    
Croatia HR    
Czech Republic CZ  - - 
Denmark DK  - - 
Estonia EE    
Finland FI    
France FR    
Germany DE    
Hungary HU    
Iceland IS  - - 
Ireland IE  - - 
Italy IT    
Lithuania LT    
the Netherlands NL    
Norway NO    
Portugal PT    
Slovakia SK  - - 
Slovenia SI    
Spain ES    
Sweden SE    
United Kingdom UK    
 
4.3.2. ALLOWED WAYS OF PRESCRIBING 
Depending on the types of medicinal products available, countries allow different ways of prescribing: brand 
name prescribing, generic prescribing and INN prescribing.  
Brand name prescribing is allowed in all investigated countries, except in three: Estonia, Lithuania and Portugal. 
In these three countries, brand name prescribing is only allowed in specific situations where INN prescribing 
might compromise patient safety (see further).  
Most countries do not make a distinction between the legal status of brands and branded generics, which 
implicates that regulation for prescribing branded generics is similar to the regulation of brand name prescribing. 
However, countries might distinguish between brands and branded generics for price and reimbursement related 
reasons. For example, in Belgium, physicians are allowed to prescribe both by brand name and branded generic 
name but reimbursement regulation for brand products and branded generics causes differences in price and 
reimbursement level (Table 4.2).  
INN prescribing is possible in 15 of the investigated countries and is not allowed in Sweden. It is mandatory for 
all products (except in specific situations – see further) in Estonia, Lithuania and Portugal. In Hungary, INN 
prescribing is only mandatory for lipid-modifying agents. In Italy, it is only mandatory for off-patent products 
prescribed for acute treatment or prescribed for the first time in chronic treatment. In France, Germany, 
Hungary, the Netherlands, Spain, Slovenia and the UK INN prescribing is allowed (but not mandatory, except for 
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lipid-modifying agents in Hungary) for all products. The same applies to Finland and Norway, but it is rarely used. 
In Belgium, INN prescribing is allowed for most products, but exemptions apply (see further) (Table 4.2 & 4.3).  
Table 4.2. Overview of the applied regulation1 of medicines prescribing and generic substitution 
 
Country 
Brand name prescribing 
= prescribing of branded 
generics2 
INN prescribing Generic substitution 
Belgium  Allowed for all products 
 
Allowed, but with 
exemptions3 
 
Not allowed 
Croatia  Mandatory for all products 
 
Allowed for all products 
 
Allowed, but with 
exemptions3 
Estonia 
 
Not allowed, only in specific 
situations4 
 
Mandatory for all products 
 
Allowed 
Finland  Allowed for all products 
 
Allowed for all products, but 
rarely used 
 
Mandatory, but with 
exemptions 
France  Allowed for all products 
 
Allowed for all products 
 
Mandatory, but with 
exemptions3 
Germany  Allowed for all products 
 
Allowed for all products 
 
Mandatory, but with 
exemptions3 
Hungary 
 
Allowed for all products, 
except lipid-modifying 
agents 
 
Allowed, mandatory for 
lipid-modifying agents 
 
Allowed 
Italy 
 
Allowed, except for off-
patent products prescribed 
for acute treatment or for 
the 1st time in chronic 
treatment 
 
Mandatory for off-patent 
products prescribed for 
acute treatment or for the 
1st time in chronic 
treatment 
 
Allowed, but with 
exemptions3 
Lithuania 
 
Not allowed, only in specific 
situations4 
 
Mandatory for all products, 
except biologicals and 
narrow therapeutic index 
drugs (antiepileptic agents 
and immunosuppressive 
agents) 
 
Not allowed 
the 
Netherlands 
 
Allowed for all products 
 
Allowed for all products 
 
Allowed, but with 
exemptions3 
Norway  Allowed for all products 
 
Allowed for all products, but 
rarely used 
 
Mandatory, but with 
exemptions3 
Portugal 
 
Not allowed, only in specific 
situations4 
 
Mandatory for all products, 
except for tacrolimus, 
ciclosporin and L-thyroxin 
 
Not allowed 
Slovenia  Allowed for all products 
 
Allowed for all products 
 
Allowed for all products 
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4.3.3. GENERIC SUBSTITUTION 
More than half of the countries allow both INN prescribing and generic substitution (DE, EE, FI, FR, HU, IT, NL, 
NO, SI and ES), but usually either INN prescribing or generic substitution is endorsed for rational drug utilization 
and as cost-containment measure (Table 4.2).  
Generic substitution is allowed in six countries (HR, EE, HU, IT, NL and SI) and mandatory in Finland, France, 
Germany, Norway, Spain and Sweden, but exemptions apply. It is not allowed in Belgium, Lithuania, Portugal and 
the UK (Table 4.2).  
It is important to notice that most of the above described regulation is (only) applicable for reimbursable medical 
products and that different regulation can apply for non-reimbursable products and Over-The-Counter (OTC) 
products.   
4.3.4. EXEMPTIONS AND SPECIFIC SITUATIONS 
The regulation of INN prescribing and generic substitution is elaborated in different ways and extent across 
countries. For example, countries can apply lists of interchangeable products or lists of products not suitable for 
INN prescribing or generic substitution.  
Twelve countries (BE, DE, FI, FR, HU, IT, LT, NO, PT, SE, SI and foreseen beginning 2015 in HR) established lists of 
interchangeable products for INN prescribing or generic substitution. These lists differ between countries with 
regard to the items (e.g. active ingredient name, brand name, strength, route of administration) used to establish 
the interchangeable groups. In some countries, these lists of interchangeable products are related to national 
reimbursement policies and in some countries only medicinal products for which generics are available are 
included.
Spain  Allowed for all products 
 
Allowed for all products 
 
Mandatory, but with 
exemptions3 
Sweden  Allowed for all products 
 
Not allowed 
 
Mandatory, but with 
exemptions3 
United 
Kingdom 
 
Allowed for all products 
 
Allowed for all products 
 
Not allowed 
1This regulation is only applicable for reimbursable medical products and different regulation can apply for 
non-reimbursable products and Over-The-Counter products. 
2Because there is no legal distinction between brands and branded generics. However, there might be a 
difference between brands and branded generics with regard to pricing and reimbursement regulation. 
3These exemptions differ between countries, but can include anti-arrhythmia agents, antiepileptic agents, 
biologicals and biosimilars, cardiac glycosides, coumarin anticoagulants, immunosuppressive agents, insulin 
and analogues and thyroid hormones. See also Table 4.3. 
4These specific situations refer to, for example, prescriptions for chronic treatment, patients with special 
needs (children, elderly) or sensitivity to excipients or when judged necessary by the prescriber for patient 
safety reasons. 
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Table 4.3. Overview of most common groups of products exempted from INN prescribing and/or generic substitution1 
Country 
Anti-
arrhythmia 
agents 
Antiepileptic agents Biologicals & biosimilars 
Cardiac 
glycosides 
Coumarin 
anticoagulants 
Immunosuppressive 
agents 
Thyroid 
hormones 
Products 
used with 
specific aids2 
Belgium 
Exempted 
from 
switching 
All exempted from 
switching 
Exempted 
from INN 
prescribing 
Exempted from 
switching 
Exempted from 
switching 
Exempted from 
switching 
Exempted 
from 
switching 
Exempted 
from 
switching 
Croatia - - - 
Digoxin 
exempted from 
generic 
substitution 
Warfarin 
exempted from 
generic 
substitution 
Cyclosporin and 
tacrolimus exempted 
from generic 
substitution 
- 
Exempted 
from generic 
substitution 
Estonia No explicit exemptions for INN prescribing; brand name prescribing only allowed for medical reasons 
Finland 
Exempted 
from generic 
substitution 
Exempted from 
generic substitution 
Exempted 
from generic 
substitution 
Exempted from 
generic 
substitution 
Warfarin 
exempted from 
generic 
substitution 
- - 
Exempted 
from generic 
substitution 
France - 
Levetiracetam, 
lamotrigine, 
topiramate and 
valproic acid 
exempted from 
generic substitution 
- - - 
Mycophenolate mofetil 
exempted from generic 
substitution 
L-thyroxin 
exempted 
from generic 
substitution 
- 
Germany 
Substitution 
should be 
carefully 
considered 
Substitution should 
be carefully 
considered 
Substitution 
should be 
carefully 
considered 
Substitution 
should be 
carefully 
considered 
Substitution 
should be 
carefully 
considered 
Substitution should be 
carefully considered 
Substitution 
should be 
carefully 
considered 
Substitution 
should be 
carefully 
considered 
Hungary No explicit exemptions for INN prescribing or generic substitution. A list of substitutable medicinal products is available. 
Italy No explicit exemptions for INN prescribing or generic substitution. A list of substitutable medicinal products is available. 
Lithuania - Exempted from INN prescribing 
Exempted 
from INN 
prescribing 
- - Exempted from INN prescribing - - 
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Country 
Anti-
arrhythmia 
agents 
Antiepileptic agents Biologicals & biosimilars 
Cardiac 
glycosides 
Coumarin 
anticoagulants 
Immunosuppressive 
agents 
Thyroid 
hormones 
Products 
used with 
specific aids2 
the 
Netherlands 
Class I and III 
exempted 
from 
substitution 
Exempted from 
generic substitution 
when indicated for 
epilepsy 
Substitution 
should be 
carefully 
considered 
Exempted from 
substitution 
Exempted from 
substitution 
Exempted from 
substitution when 
indicated for 
prophylaxis of graft-
versus-host disease 
Exempted 
from 
substitution 
Exempted 
from 
substitution 
Norway - 
All exempted from 
generic substitution 
but only when 
indicated for 
epilepsy 
- - - - 
L-thyroxin 
exempted 
from generic 
substitution 
- 
Portugal - - - - - 
Cyclosporin and 
tacrolimus exempted 
from generic 
substitution 
L-thyroxin 
exempted 
from generic 
substitution 
- 
Slovenia No explicit exemptions for INN prescribing or generic substitution. A list of substitutable medicinal products is available. 
Spain 
Flecainide 
exempted 
from generic 
substitution 
Carbamazepine, 
phenytoin and 
vigabatrin exempted 
from generic 
substitution 
Exempted 
from generic 
substitution 
Digoxin and 
metildigoxin 
exempted from 
generic 
substitution 
Exempted from 
generic 
substitution 
Cyclosporin and 
tacrolimus exempted 
from generic 
substitution 
L-thyroxin 
exempted 
from generic 
substitution 
Exempted 
from generic 
substitution 
Sweden - Exempted from generic substitution - - - 
Exempted from generic 
substitution - 
Exempted 
from generic 
substitution 
United 
Kingdom - 
Advised to prescribe 
by brand name 
Advised to 
prescribe by 
brand name 
- - Advised to prescribe by brand name 
Advised to 
prescribe by 
brand name 
Advised to 
prescribe by 
brand name 
1Some countries only took into account active ingredients and medicinal products available on the national pharmaceutical market, or active ingredients for which 
generics were available. 
2These products can be e.g. inhalation medication, prefilled syringes with adrenaline, insulin pens, … 
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In twelve countries (BE, DE, ES, FI, FR, HR, LT, NL, NO, PT, SE and UK) explicit lists of medical products which 
cannot be prescribed by INN or substituted are established. These lists differ between countries in terms of 
products included and whether they are binding or advisory. Nine countries (BE, ES, FI, FR, HR, LT, NO, PT and 
SE) have binding lists with (groups of) products exempted from INN prescribing (BE and LT) or generic 
substitution. In the United Kingdom, a document from the National Health Service is available on which (groups 
of) products are advised to prescribe by brand name instead of by INN. In Germany, the German Pharmaceutical 
Society (Deutsche Pharmazeutische Gesellschaft e.V. – DPhG [18]) has established a guidance on Good 
Substitution Practice, which includes (groups of) products where substitution should be carefully considered. In 
the Netherlands, a guidance on generic substitution is established by the professional association for pharmacists 
(Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie – KNMP [19]) and exempt antiepileptic 
drugs (AEDs) when prescribed for epilepsy, immunosuppressive agents and insulin and its analogues from generic 
substitution and advises to carefully consider substitution for other (groups of) products (e.g. cardiac glycosides, 
coumarin anticoagulants). Besides a binding list with products not suitable for INN prescribing, Belgium applies 
a second list with exemptions, the ‘NO SWITCH’ list. This list contains (groups of) products for which frequent 
switching during treatment is not advised. Switching can occur when dispensing an INN prescription, but not due 
to generic substitution, as this is not allowed in Belgium [10,14].  
Exemptions for INN prescribing and/or generic substitution can be listed as specific active ingredients (e.g. 
cyclosporin, tacrolimus, warfarin) or as groups of products (e.g. AEDs, immunosuppressive agents). Some 
countries refer to these (groups of) products as narrow-therapeutic index drugs (NTIDs). However, within the 
Europe, there is no official definition of an NTID nor is there an exhaustive list of NTIDs. As a result, products 
judged as NTIDs also differ widely between countries.   
Ten countries exempt antiepileptic agents and immunosuppressive agents. Both groups are exempted in 
Belgium, France (only specific AEDs and mycophenolate mofetil), Germany, Lithuania, the Netherlands, Spain 
(only specific active ingredients), Sweden and the UK. In Croatia, only cyclosporine and tacrolimus are exempted. 
In Norway, only AEDs prescribed for the treatment of epilepsy are exempted. Thyroid hormones are exempted 
in eight countries (BE, DE, FR, NL, NO, PT, SE and UK). Six countries (BE, DE, ES, FI, HR and NL) exempt coumarin 
anticoagulants and cardiac glycosides. Anti-arrhythmia agent are exempted by five countries (BE, DE, ES, FI and 
NL). Further details on exempted (groups of) products are given in Table 4.3. Besides the mentioned groups of 
products in Table 4.3, multiple other (groups of) products are listed as exemptions in different countries, which 
include controlled drugs (e.g. buprenorphine in France), medicated patches or transdermal systems (e.g. in BE, 
DE, FI, SE, UK), products with modified release (e.g. products containing nifedipine or morphine) and products 
containing multiple active ingredients (e.g. laxatives, multiphasic contraceptive pills).  
Some countries (e.g. BE, IT, PT) also describe specific situations where INN prescribing, generic substitution or 
frequent switching might not be appropriate for practical or patient safety reasons. These specific situations refer 
to, for example, prescriptions for chronic treatment, patients with special needs (children, elderly) or sensitivity 
to excipients.  
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All countries applying mandatory policies on INN prescribing or generic substitution allow prescribers to deviate 
from the applying rules when judged necessary for patient safety reasons. In most countries, substitution of 
aforementioned products is also possible in exceptional situations (e.g. stock problems) with supervision of the 
prescriber. 
4.4. DISCUSSION 
To the best of our knowledge, this study was the first to investigate exemptions related to INN prescribing and 
generic substitution. These exemptions are mainly referred to as narrow therapeutic index drugs (NTIDs). 
Remarkably, these exemptions also differ widely between countries, although most of them were established 
because of patient safety reasons – and patients do not differ between countries. In addition, within Europe, 
there is no official definition of a NTID or an exhaustive list of NTIDs, neither is there a list of products which are 
advised not to be switched or substituted during treatment (without the supervision of a physician and/or 
pharmacist). 
Not all European countries were included in our study. On the world wide web more complete overviews of the 
allowed ways of prescribing and of generic substitution are available, including data on the remaining 13 EU 
member states (AT, BG, CZ, CY, DK, EL, IE, LV, LU, MT, PL, RO and SK) [20,21]. These overviews confirm our data 
for the common countries and complement it for the remaining countries.   
Despite the use of a glossary, definitions of used terms (e.g. generic products, brand name prescribing, generic 
prescribing) can have subtle differences between countries. These differences can be explained by variations in 
pricing and reimbursement regulation, which was not a topic in our questionnaire. In-depth understanding of all 
national aspects related to medicines and prescribing regulation is only possible when the overall picture is 
revealed.  
When comparing (groups of) products exempted from INN prescribing and/or generic substitution, not all 
products and differences between countries were discussed, due to the large variety between countries. In our 
study, we only focused on the eight main groups of exemptions and discussed some others briefly. However, our 
purpose was to highlight the wide variability between European countries in exemptions related to the same 
pharmaceutical policies.  
Furthermore, no data on the amount of prescriptions and dispensed products has been collected for the included 
countries. Combined with our collected information, it would be interesting to investigate for each country the 
effect of the applied policies (e.g. the percentage generic market share, percentage of generic substitution in the 
pharmacy). However, collecting these data will be a difficult task, as one way of prescribing can result in different 
types of products dispensed. For example, an INN prescription can lead to the dispensing of either a brand 
product or a generic product (branded or unbranded).  
Based on the information from 16 different European countries, we can make some recommendations for the 
exemptions related to INN prescribing and/or generic substitution. A European guideline might exempt anti-
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arrhythmia agents, biologicals and biosimilars, cardiac glycosides, coumarin anticoagulants, thyroid hormones 
and products used with specific aids. In the Netherlands, immunosuppressive agents are only exempt when 
indicated for the prophylaxis of graft-versus-host disease. Similarly, they only exempted antiepileptic agents 
when indicated for epilepsy. It should be discussed whether or not to take into account the indication of certain 
medicinal products before exempting them.  
We also recommend to describe specific situations where INN prescribing and/or generic substitution is not 
advised (e.g. chronic treatment). In addition, the guideline should also include the possibility for prescribers to 
object towards switching and/or substitution for patient safety reasons.  
Finally, when establishing a guideline for patient safety reasons, it is recommendable to take into account the 
economic implications of exempting products and situations. It should be investigated whether the intended cost 
savings through INN prescribing and/or generic substitution compensate for the potential costs related to 
adverse drug reactions (ADRs) due to switching and/or substitution.  
4.5. CONCLUSION 
National prescribing regulation differs widely between European countries. In particular the wide variability in 
exemptions related to INN prescribing and generic substitution and the lack of a definition for narrow therapeutic 
index drugs highlight the need for consensus. The results of our study can serve as a basis for the competent 
European authorities to establish a common guideline on this subject. 
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ABSTRACT 
Objective. To investigate interchangeability of gabapentin 800 mg tablets marketed as Neurontin® and 
Gabasandoz® following FDA guidelines using the individual bioequivalence (IBE) approach. To investigate 
interchangeability in a more real-life situation through IBE by including two different batches of each product 
(Neurontin® Batch ‘A’ and ‘B’, Gabasandoz® Batch ‘A’ and ‘B’). 
Methods.  Thirty healthy subjects received 6 times - in randomized order - a single dose of 800 mg Neurontin® 
(Batch ‘A’ or ‘B’) or 800 mg Gabasandoz® (Batch ‘A’ or ‘B’). Serum concentrations of gabapentin up to 36 hours 
after dosing were determined. According to FDA guidelines, IBE can be established if the 95 % upper-confidence 
bound (UCB) of η (i.e. a function of different variance terms) is lower than the IBE limit θI, which is 2.5. For AUC0-
inf and Cmax, η and its 95 % UCB were calculated. 
Results. For AUC∞ and Cmax η was 0.58 and 0.19, respectively, and the 95 % UCB was 1.32 and 0.63 (both p-value 
< 0.001), respectively. When including data on batch ‘B’ of Neurontin® and Gabasandoz®, η was 0.46 and -0.08 
for AUC0-inf and Cmax, respectively. The 95 % UCB was 1.20 and 0.40, respectively (both p-value < 0.001). All UCB 
were below the IBE limit θI, showing IBE.  
Conclusion. This study indicates that Neurontin® 800 mg (Batch ‘A’) and Gabasandoz® 800 mg (Batch ‘A’) are 
individual bioequivalent and interchangeable in clinical practice. This interchangeability remains when 
resembling a more real-life situation by adding an additional batch of each product (Batch ‘B’). 
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5.1. INTRODUCTION 
Once the patent of a marketed drug product has expired, generic drug products can enter the market [1,2] of 
which the requirements and characteristics are secured by regulatory authorities (such as the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA)) [3]. For generic drug products, prior to enter 
the market, it is required to establish (average) bioequivalence (ABE) with the reference (marketed) drug 
product. Two medicinal products are considered bioequivalent if the 90 % confidence interval of the ratio in 
bioavailability (AUC and Cmax) between these products after administration of the same dose lies within a 
predefined interval [4]. This interval is between 80 % and 125 % for most medicinal products or between 90 % 
and 111 % for narrow therapeutic index drugs (NTIDs). These intervals are defined to ensure comparable in vivo 
performance, i.e. similarity in terms of safety and efficacy, between the reference and generic drug product [5]. 
Notwithstanding these bioequivalence trials, issues related to switching from reference drug product to generics 
and between generics have been reported, especially for narrow therapeutic index drugs (NTIDs) [6], anti-
epileptics [7–9], antipsychotics [10–13], and antidepressants [14].  
Taking these reports into account, prioritizing patients safety and in line with other European countries [15–17], 
the Belgian medicines agency (Federal Agency for Medicines and Health Products (FAMHP) [18]) established an 
exhaustive list of products for which switching from reference drug product (brand) to generic and vice versa or 
between generics is not advised [19,20]. This list is titled the ‘NO SWITCH’-list and is established within the 
framework of operationalizing electronic International Nonproprietary Name (INN) prescribing in Belgium [20]. 
INN prescribing in Belgium can result more frequent switching between drug products containing the same 
compound [21,22]. The ‘NO SWITCH’-list contains products such as NTIDs, very toxic compounds and all 
antiepileptic drugs (AEDs). Being on this list implies that once treatment is started with a medicinal product from 
a manufacturer, it is advised to continue treatment with exactly the same product. This can be advised because 
switching towards a medicinal product with different appearance can cause medication nonadherence [23]. In 
addition, it can also be advised because it is believed that products from different manufacturers are not 
(completely) interchangeable, in particular between-batch variability of a drug product is believed to be smaller 
than the variability between two bioequivalent products from different manufacturers.  
The overall goal of this study was to investigate the interchangeability between a brand product (NEURONTIN® 
800 mg) and its generic counterpart (GABASANDOZ® 800 mg) of gabapentin on the ‘NO SWITCH’-list. To the best 
of our knowledge, for none of the products on the ‘NO SWITCH’-list interchangeability has been studied using 
the appropriate clinical trials. In this context, a trial to establish individual bioequivalence (IBE) was performed 
as IBE is described as an appropriate method to investigate interchangeability between products [24]. The 
average bioequivalence trial design is not suitable, as it does not take into account within-subject variability 
[24,25].  
Because of the 4-way crossover design, complex statistics and financial burden of the IBE approach and the fact 
that interchangeability establishment is not always needed for patients’ safety, for a majority of medicinal 
products, ABE currently remains the standard bioequivalence method [24,26–28]. For bioequivalence testing in 
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anti-epileptics, Midha et al. (2005) [29] and Bailer and Midha (2010) [30] proposed the Scaled Average 
Bioequivalence approach (sABE), which is ABE testing where the variance of the reference formulation is taken 
into account. However, this sABE approach also dictates the use of a 4-way crossover design and more complex 
statistics than ABE.  
In this study, gabapentin, an antiepileptic drug on the ‘NO SWITCH’-list is used as study compound, with 
NEURONTIN® 800 mg as brand (the reference drug product) and GABASANDOZ® 800 mg as generic counterpart. 
Gabapentin is well absorbed without food-effect and peak plasma concentrations are reached within two to four 
hours after oral administration [31,32]. There is no metabolization in humans and gabapentin is eliminated as 
such by renal excretion [31]. The reported half-life ranged from five to ten hours [31,32].  
The aim of this study was two-fold, starting with investigating for the first time IBE between one batch of the 
reference drug product (R1) and one batch of a generic (T1) of 800 mg gabapentin, using a four-way cross-over 
study design. This is in contrast to the study of Yu et al., where the so-called ‘drift’-effect was investigated 
between different generics of 800 mg gabapentin but IBE could not be established because of the lack of a 
replicated study design [32]. The second aim was to investigate the between-batch variability between two 
different batches of the reference drug product (R1 & R2) and two different batches of the generic (T1 & T2), 
using a six-way cross-over design. This additional effort was made because this design more closely resembles 
the real-life situation where patients consecutively receive different batches of their treatment. 
5.2. METHODS & MATERIALS 
All trial procedures (except the serum gabapentin analyses) were performed at the Drug Research Unit Ghent, 
the unit for early phase clinical drug research of the Ghent University Hospital, Belgium (www.drug-uzgent.be).  
5.2.1. TREATMENTS 
Four different treatments were administered. The reference products were two different batches of 
NEURONTIN® 800 mg [Pfizer®, New York, USA] (Batch A with number 1269012 and expiry date 12/2013; Batch B 
with number 1091082 and expiry date 07/2014) referred to as R1 and R2, respectively. The test products were 
two different batches of GABASANDOZ® 800 mg [Sandoz®, Holzkirchen, Germany] (Batch A with number CJ7435 
and expiry date 11/2014; Batch B with number CT9850 and expiry date 03/2015), referred to as T1 and T2, 
respectively.  
5.2.2. STUDY DESIGN 
The study was a single blind, single dose, randomized six-way cross-over study in health volunteers. To 
investigate individual bioequivalence (IBE) between reference and test product, R1 and T1 were given in a 
replicated, two-sequence, randomized order (R1/T1/R1/T1 or T1/R1/T1/R1). This fixed design allowed an 
estimation of the within-subject variance and the subject-by-formulation interaction. To investigate the IBE 
between different batches of reference and test, two periods were added where R2 and T2 were administered 
in randomized order, before and/or after the fixed design with R1 and T1 (Figure 5.1), resulting in 12 possible 
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combinations. Therefore, randomization was performed in blocks of 12. A minimum of four days wash-out 
separated the single-doses of Period 1 to 6 to minimize the risk of drug carryover.   
Figure 5.1. Summary of the study design with the two-sequence fixed design (R1/T1/R1/T1 or T1/R1/T1/R1) 
and the additional batches of reference (R2) and test (T2) before and/or after the fixed design 
 
With R1 NEURONTIN® 800 mg Batch A, R2 NEURONTIN® 800 mg Batch B, T1 GABASANDOZ® 800 mg Batch A 
and T2 GABASANDOZ® 800 mg Batch B. 
In each period, subjects were confined in the clinical research unit from the evening before study drug 
administration until 12 hours after dosing. They were fasted overnight for at least 8 hours and received, 
blindfolded, a single, oral dose of 800 mg gabapentin in the morning (starting at 09:00 AM), which was taken 
with approximately 240 mL of noncarbonated water. Subjects received a standardized lunch, snack and dinner 
at respectively 4, 7 and 10 hours after dosing. 
This study was conducted in two parts, starting with 12 subjects to collect data to determine the total sample 
size, as at that time no information on 800 mg doses was available in literature. In part two, additional subjects 
were included to achieve the FDA’s recommended 80 % power. 
5.2.3. STUDY POPULATION: IN- AND EXCLUSION CRITERIA 
The subjects were non-smokers, aged between 18 and 55 years, and had a Body Mass Index of 18.0 to 30.0 
kg/m². All subjects were in good physical and mental health at the time of inclusion as established by medical 
history, physical examination, electrocardiogram (ECG) and vital signs recording, and by results of biochemistry, 
hematology and urinalysis testing within six weeks prior to the first dose. Subjects had no history of 
hypersensitivity or idiosyncrasy to gabapentin or any other antiepileptic drugs, reported no history of alcohol or 
drug abuse within the last two years, no cancer or surgery of gastro-intestinal tract that might interfere with 
absorption and no history or presence of any significant disease. There was no use of any medication (except for 
contraceptive agents and paracetamol), herbal medicines or dietary supplements from 14 days prior to the first 
dose. Subjects refrained from any enzyme inducing drugs and products from 21 days prior to the first dose and 
did not participate in another clinical trial within 28 days prior to the first dose. Female subjects were not 
pregnant or breastfeeding, and agreed to apply a highly effective method of birth control. All subjects were 
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informed, orally and in writing, about this study and gave oral and written consent prior to enter the study and 
were willing to comply with the study protocol requirements and to complete the study.  
This study was performed in accordance with the study protocol, the ethical principles of the Declaration of 
Helsinki [24], International Conference of Harmonization (ICH) – Good Clinical Practice (GCP) Guidelines [25], EU-
GCP directives [26] and the applicable national regulatory requirements [27]. This study was approved by the 
ethics committee of the Ghent University Hospital (EC/2013/210) and received EudraCT-number 2013-001157-
57. The study was registered in the clinicaltrials.gov database (ID number NCT01821235). 
5.2.4. MEASUREMENTS 
Blood samples for pharmacokinetic measurements were taken prior to gabapentin administration, and at 1, 1.5, 
2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 24 and 36 hours after dosing. For blood samples after discharge (24 and 36 
hours postdose), subjects returned to the clinical research unit. Approximately 2 mL of blood was taken by an 
indwelling catheter in the forearm into a blood collection tube with serum cloth activator without gel separator. 
Prior to each sample collection, about 1 mL of blood was drawn from the catheter and discarded. After clotting 
for at least 30 minutes, serum was separated within 2 hours after sampling, by centrifugation at 1300 g at 20°C 
for 15 minutes. Serum was transferred into cryogenic vials (Biosigma®) and stored at -20°C until analysis.  
5.2.5. BIOANALYSIS 
The analysis of gabapentin in serum was performed with a validated ultra-performance liquid chromatography 
with mass-spectrometric detection (UPLC-MS-MS). Further details of this analytical method are beyond the 
scope of this article and are presented elsewhere [33]. All analyses were performed at the department of clinical 
pharmacology and pharmacy of the VU University Medical Center, Amsterdam, The Netherlands 
(http://www.vumc.nl/afdelingen/klinische-farmacologie-apotheek/). 
5.2.6. STATISTICAL ANALYSIS 
Secondary pharmacokinetic (PK) parameters were calculated using non-compartmental analysis with the PK 
package in R® [34,35]. The secondary PK parameters necessary for establishment of individual bioequivalence 
(IBE) were the area under the curve, from time 0 to infinity (AUC0-inf) and the maximum plasma concentration 
(Cmax). Other secondary PK parameters, plasma elimination half-life, Tmax and AUC0-t were solely included in the 
descriptive part of the results. The area under the curves, and the half-life were estimated using the PK package, 
whereas the time to reach Cmax (Tmax) and the Cmax were determined from the observed plasma concentration-
time profiles.  
The statistical tests to establish average and individual bioequivalence were performed according to the FDA 
Guidance for Industry on “Statistical approaches to establishing bioequivalence” [25], from now referred to as 
‘the guidance’.  
Using the data from part I of the study, initial estimates were obtained for σD (the subject-by-formulation 
interaction term), σT and σR (the within-subject variability for test and reference, respectively). Based on these 
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initial estimates, a simulation study was performed in R® to determine the total sample size necessary to comply 
with the FDA’s proposed power of 80 %. The R® script included the generation of 1000 virtual clinical trials, with 
a pre-specified sample size (for 12, 14, 16, …, 40 subjects) with within-product variability and subject-by-
formulation interaction randomly sampled from the initial estimates of the σD, σT and σR distributions and 
allowing for a (μT - μR) to be equal to 5 % (according to the guidance). Afterwards, for each of the virtual clinical 
trials, the IBE criterion was calculated and the power was estimated by calculating the relative frequency of 
virtual clinical trials, in each of the sample size categories, which concluded IBE.   
Afterwards, in the final analysis, average bioequivalence (ABE) was assumed if  
−𝜃𝜃𝐴𝐴 < (𝜇𝜇𝑇𝑇 − 𝜇𝜇𝑅𝑅) < 𝜃𝜃𝐴𝐴 
with θA = ln(1.25) and, µT and µR being the population average log-transformed AUC or Cmax for the test and 
reference formulation, respectively. The 90 % confidence intervals for the ABE criteria were estimated using SAS® 
version 9.4 [36], by fitting the data using a linear mixed-effects model according the guidance. 
Once average bioequivalence was established, the analysis to investigate IBE between R1 and T1 for AUC0-inf and 
Cmax was performed. According to the guidance, IBE is established once the 95 % upper confidence bound (UCB) 
of η is lower than the specified limit θI. η is a function of population measures, described in the guidance and 
includes µT and µR, subject-by-formulation interaction variance and within-subject variance of the test and 
reference drug product. The IBE limit θI was calculated as follows: 
𝜃𝜃𝐼𝐼 =  (𝑙𝑙𝑙𝑙1.25)2 + 𝜀𝜀𝐼𝐼(𝜎𝜎𝑊𝑊0)2  
with εI = 0.05 and σW0 = 0.2. εI is the sum of the maximum allowed estimate of the subject-by-formulation 
interaction (σD², i.e. maximum 0.03) and the difference in the within-subject variability (σWT² - σWR², i.e. 0.02). 
σW0² is the specified constant within-subject variance. As gabapentin is a low variability product with a wide 
therapeutic range, the constant-scaling approach was used as recommended in the guidance.  
Since no analytical solution has been documented in literature to calculate the 95 % upper confidence bound 
(UCB) of η,  a script was written in R® [34] to estimate the confidence interval from a bootstrap distribution.  
Afterwards, we included additional data on the oral administration of R2 and T2. Similar to the previous part, the 
analysis started with calculating the ABE, and once established, the IBE analysis was performed. In addition to 
the general structure of the linear-mixed effects model proposed, an additional variance term, i.e. σbatch, was 
included to account for the additional variability by introducing two different batches (R2 and T2), instead of just 
one batch of each product. 
In addition, to establish whether the between-batch variability was different from the variability between two 
bioequivalent products, an independent samples T-test was performed, using SPSS® (IBM Corp. Released 2011. 
IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.) with the 0.05 significance level.  The 
The interchangeability of gabapentin 800 mg tablets 
107 
 
absolute differences of AUC0-t, AUC0-inf, Cmax and Tmax between the two batches of the reference product (|R1 – 
R2|) and the reference and test product (|R1 – T1|, |R1 – T2|, |R2 – T1| and |R2 – T2|) were used.  
5.2.7. SAFETY ANALYSIS 
Adverse events (AEs) were checked and reported at every visit, from signing the Informed Consent Form (ICF) 
onwards until the last study-related visit (follow-up). For each AE, the duration and intensity was documented 
and the causality to the study treatment was evaluated. 
5.3. RESULTS 
5.3.1. STUDY POPULATION 
Part I of this study was performed between March and May 2013 and part II between August and October 2013. 
This two-part study enrolled, in total, 30 healthy subjects, of which 29 completed the study. Part I included 12 
subjects (3 men and 9 women) and part II 18 (7 men and 11 women). One participant in part II (allocation number 
022) withdrew consent for further blood sampling and medication intake during the fourth period of the study.  
Demographic characteristics of the study population are shown in Table 5.1.  
Table 5.1. Demographic characteristics of the study population 
Subject 
number Sex Age (years) Weight (kg) Height (cm) BMI (kg/m²) 
Part I 
01 F 25 56.4 173.0 18.8 
02 F 43 51.2 154.0 21.6 
03 F 51 59.6 180.5 18.3 
04 M 50 95.8 179.5 29.7 
05 F 22 59.4 163.0 22.4 
06 F 22 86.8 172.0 29.3 
07 F 24 49.8 158.0 19.9 
08 F 54 73.8 157.0 29.9 
09 F 36 74.2 176.0 23.9 
10 M 24 81.4 191.5 22.2 
11 F 46 72.6 165.0 26.7 
12 M 37 76.2 175.5 24.7 
Part II 
13* M 48 84.8 168.5 29.9 
14* F 25 61.2 161.0 23.6 
15 M 55 94.0 178.0 29.7 
16 M 55 76.8 178.0 24.2 
17 F 50 74.8 159.0 29.6 
18 F 22 59.6 163.5 22.3 
19 M 42 81.4 180.0 25.0 
20 F 37 74.8 169.0 26.2 
21 M 27 88.4 184.5 26.0 
22* M 24 65.6 179.5 20.4 
23 F 24 55.6 164.0 20.6 
24 M 30 93.4 181.0 28.5 
25 F 49 66.8 168.5 23.5 
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Subject 
number Sex Age (years) Weight (kg) Height (cm) BMI (kg/m²) 
26 F 22 65.8 164.0 24.5 
27 F 42 60.8 160.0 23.8 
28 F 22 64.8 160.5 25.2 
29 F 25 57.4 171.5 19.5 
30 F 20 65.4 159.5 25.7 
Mean 35.1 71.0 169.8 24.5 
SD 12.4 13.0 9.6 3.5 
F: female; M: male 
*Data of these subjects were not used in the statistical analysis due to incomplete data 
 
5.3.2. PHARMACOKINETICS 
Due to problems during blood sampling, blood samples are missing for two subjects (allocation number 013 and 
014). Therefore, data on 27 subjects were used for the estimation of the secondary pharmacokinetic parameters 
and the bioequivalence criteria (Table 5.1).  
Mean plasma concentration time-curves per treatment are shown in Figure 5.2 and mean AUC0-t, AUC0-inf, Cmax, 
Tmax and T1/2 for each treatment are presented in Table 5.2. In 1.7 % of the cases, the gabapentin concentration 
was below the lower limit of quantification at 12 hours postdose, in 16.4 % of the cases at 24 hours postdose and 
in the remaining cases at 36 hours postdose. 
The mean AUC0-inf for the different treatments ranged from 85.64 to 86.73 mg.h/L, the mean Cmax from 5.19 to 
5.23 mg/L and the mean T1/2  ranged from 10.88 to 10.89 hours for all four treatments (Table 5.2).  
For R1 and T1, the difference between average log-transformed AUC0-inf and Cmax and their 90 % confidence 
intervals are shown in Table 5.3. Both were within the 80 % and 125 % ranges, thereby not rejecting ABE. 
Table 5.2. Mean (SD) of AUC0-t, AUC0-inf, Cmax, Tmax and T1/2 with N = 27 
Product Reference/Test AUC0-t (mg.h)/L 
AUC0-inf 
(mg.h)/L 
Cmax 
(mg/L) 
Tmax 
(h) 
T1/2 
(h) 
NEURONTIN® 800 mg 
Batch A 
Reference 1  
(R1) 
79.35 
(28.11) 
86.15 
(31.79) 
5.20 
(1.42) 
4.32 
(1.45) 
10.88 
(1.95) 
NEURONTIN® 800 mg 
Batch B 
Reference 2  
(R2) 
79.96 
(28.67) 
86.73 
(32.24) 
5.23 
(1.43) 
4.35 
(1.47) 
10.88 
(1.94) 
GABASANDOZ® 800 mg 
Batch A 
Test 1 
(T1) 
78.84 
(27.63) 
85.64 
(31.36) 
5.19 
(1.41) 
4.29 
(1.44) 
10.89 
(1.96) 
GABASANDOZ® 800 mg 
Batch B 
Test 2 
(T2) 
79.59 
(28.21) 
86.35 
(31.85) 
5.21 
(1.42) 
4.34 
(1.46) 
10.88 
(1.95) 
AUC0-t: area under the drug concentration-time curve from time zero to 36 hours; AUC0-inf: area under the 
drug concentration-time curve from time zero to infinity; Cmax: peak plasma concentration; Tmax: time to peak 
concentration; T1/2: elimination half-life.  
The 95 % upper-confidence bounds (UCBs) of the IBE criteria for AUC0-inf and Cmax are shown in Table 5.4. Both 
were below IBE limit of 2.5, as proposed by the FDA, thereby confirming individual bioequivalence between 
NEURONITN® 800 mg Batch A (R1) and GABASANDOZ® 800 mg Batch A (T1) (Figure 5.2).  
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Figure 5.2. Plasma concentration-time curve of gabapentin  
 
N = 27 healthy volunteers. Mean (± SD) concentration, with R1 = NEURONTIN® 800 mg Batch A (mean of both 
administrations), R2 = NEURONTIN® 800 mg Batch B, T1 = GABASANDOZ® 800 mg Batch A (mean of both 
administrations) and T2 = GABASANDOZ® 800 mg Batch B 
 
When including an additional batches of each product (NEURONTIN® 800 mg Batch B (R2) and GABASANDOZ® 
800 mg Batch B (T2)), ABE was also established (Table 5.3). The 95% UCBs for AUC0-inf and Cmax also remained 
below the IBE limit of 2.5 when adding data of the two additional batches, confirming individual bioequivalence 
for all products (Table 5.4).  
Table 5.3. Average bioequivalence (ABE) analysis results for AUC0-inf and Cmax parameters and bioequivalence 
(BE) conclusion 
 AUC0-inf Cmax 
 (µT – µR) 90 % CI BE conclusion (µT – µR) 90 % CI 
BE 
conclusion 
4-way crossover design with 
R1 and T1 -0.038 
-0.108 – 
0.032 Pass -0.024 
-0.088 – 
0.038 Pass 
6-way crossover design with 
R1, R2, T1 and T2 -0.041 
-0.110 – 
0.028 Pass -0.020 
-0.080 – 
0.040 Pass 
With R1 NEURONTIN® 800 mg Batch A, R2 NEURONTIN® 800 mg Batch B, T1 GABASANDOZ® 800 mg Batch A 
and T2 GABASANDOZ® 800 mg Batch B. µT and µR are the average log-transformed AUC0-inf and Cmax for the 
test and reference formulation, respectively. 90 % CI is the 90 % confidence interval for (µT - µR). 
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Table 5.4. Individual bioequivalence (IBE) analysis results for AUC0-inf and Cmax parameters, with IBE limit θ = 
2.5 and bioequivalence (BE) conclusion 
 AUC0-inf Cmax 
 
η 95 % UCB 
BE 
conclusion 
p-
value 
(η > θ) 
η 95 % UCB 
BE 
conclusion 
p-value 
(η > θ) 
4-way crossover 
design with R1 and T1 0.58 1.32 Pass < 0.001 0.19 0.63 Pass < 0.001 
6-way crossover 
design with R1, R2, T1 
and T2 
0.46 1.20 Pass < 0.001 -0.08 0.40 Pass < 0.001 
With R1 NEURONTIN® 800 mg Batch A, R2 NEURONTIN® 800 mg Batch B, T1 GABASANDOZ® 800 mg Batch A 
and T2 GABASANDOZ® 800 mg Batch B. η is a function of population measures for the estimation of IBE, and 
95 % UCB is the 95 % upper confidence bound of η. 
 
The absolute differences in AUC0-t, AUC0-inf, Cmax and Tmax between the two batches of the reference product (|R1 
– R2|) and between the reference and test product (|R1 – T1|, |R1 – T2|, |R2 – T1| and |R2 – T2|), did not differ 
significantly, showing no larger difference between batches of NEURONTIN® 800 mg and GABASANDOZ® 800 mg 
than between different batches of the same product. 
 
  Figure 5.3. Within-subject variability of AUC0-inf after replicate 
administration of reference and test 
Reference is NEURONTIN® 800 mg Batch A and test is GABASANDOZ® 800 mg Batch A.  
The bold line shows the estimated population difference (Δµ) of AUC0-inf 
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5.3.3. SAFETY & TOLERABILITY 
All treatments were moderately to generally well tolerated. Most reported adverse events (i.e. in more than 50 
% of the subjects) were somnolence (n = 24), dizziness (n = 22) and headache (n = 21). All reported adverse events 
were mild to moderate in intensity.  
There was one serious adverse event (SAE). After withdrawing consent, the subject with allocation number 022 
was hospitalized and diagnosed with substance induced psychotic disorder (caused by abuse of illicit drugs). This 
SAE was considered not related to the study drug by the investigator and the subject’s treating physician. 
5.4. DISCUSSION 
To the best of our knowledge, this study is the first to investigate individual bioequivalence (IBE) between a brand 
and generic product of gabapentin 800 mg, including two different batches of each product.  
The end-of-study analysis showed that NEURONTIN® 800 mg (Batch A) is bioequivalent to GABASANDOZ® 800 
mg (Batch A) on both the average and individual level. Average and individual bioequivalence was also proven 
when data on two different batches of each product (NEURONTIN® 800 mg Batch B and GABASANDOZ® 800 mg 
Batch B) were included, resembling a more real-life situation.  
These results can strengthen the confidence of health professionals and patients in bioequivalence and 
interchangeability between brands and generics, in particular for gabapentin.  
Between-batch variability (σbatch) was not statistically significantly different from 0, which means that no 
between-batch variance could be detected (Figure 5.3). In addition, no statistically significant differences could 
be detected when comparing within-subject differences between two batches of the reference product (|R1 - 
R2|) compared to differences between the reference and test product (|R1 - T1| and |R1 - T2|) for AUC0-t, AUC0-
inf, Cmax and Tmax. This challenges the view that between-product differences would be larger than between-batch 
differences of one product (Figure 5.3 and 5.4).  
Although our results demonstrate IBE for gabapentin 800 mg, these results can probably not be extrapolated to 
other compounds, including other AEDs, as gabapentin has a relatively simple pharmacokinetic profile (good 
absorption, no protein binding, no metabolization) [31]. 
As only one generic product of 800 mg gabapentin was available on the Belgian market, we did not include a 
second generic and could therefore not investigate whether a so-called ‘generic drift’ effect (i.e. larger 
differences between generics because each generic is only proven to be bioequivalent to the reference/innovator 
product) between different generics was present. However, previous studies with gabapentin could not detect a 
‘generic drift’ effect using a brand and three generics of 800 mg gabapentin [32,37]. Additionally, it has been 
shown from a large sample of bioequivalence studies that generic drift is unlikely to cause widespread problems 
[38].  
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Despite strict regulation by governmental authorities and many studies confirming bioequivalence between 
brands and generics, prescribers, mainly neurologists, remain reluctant towards generic AEDs and switching from 
a brand to a generic AED [39,40]. It should be asked whether this is because interchangeability between brands 
and generics is not proven or because of the uniqueness of epilepsy as disease. The first reason can be refuted 
by our results, at least for gabapentin. When it comes to the second reason, a distinction can be made between 
AEDs prescribed for epilepsy or for other indications (e.g. neuropathic pain). This latter is the case for most of 
the gabapentin prescriptions [39,41] which opens the way for additional pharmaceutical cost savings.  
A third reason for the reluctance against switching of AEDs can be the differences in tablet color and shape and 
product packaging between brand and generics. Variations in tablet appearance are proven to increase the risk 
of medication nonadherence, which can have serious consequences, in particular for patients with epilepsy [23]. 
Therefore, we are in favor of streamlining medicinal product appearance and packaging.  
5.5. CONCLUSION 
Although successful treatment is not only based on the clinical outcome of the medicinal products, but also on 
correct medication use and adherence, we can conclude that, provided correct medication use and adherence, 
switching between the brand and the generic product of 800 mg gabapentin, available on the Belgian market, 
should be possible without affecting the clinical outcomes.  
  
Figure 5.4. Within-subject variability of AUC0-inf after administration of  
2 different batches of the reference product 
 
Reference is NEURONTIN® 800 mg Batch A and Batch B.  
The bold line shows the estimated population difference (Δµ) of AUC0-inf 
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With this doctoral thesis, we aimed to investigate the different aspects of the concept of International 
Nonproprietary Name (INN) prescribing and its related policies, in Belgium and Europe. INN prescribing was 
introduced as an instrument to promote rational drug prescribing. It has a legal foundation in many European 
countries, but never really found foothold as an alternative way of prescribing, next to brand name prescribing 
and branded generic name prescribing. However, when the global financial crisis also affected Europe in 2008, 
INN prescribing was, together with generic substitution, one of the key pharmaceutical policies implemented or 
elaborated to reduce pharmaceutical expenditures. These forced cost-containment policies were not welcomed 
by all stakeholders, as they feared e.g. a negative influence on patients’ health. The implementation and 
elaboration of these policies also varied widely across European countries. In addition, there is a diversity in 
medicinal products and situations exempted from INN prescribing and generic substitution for practical and 
patient safety reasons.  
This research investigated how INN prescribing in Belgium was prepared for the implementation in electronic 
prescribing and the electronic medical record. We describe the corresponding detailed operational rules, which 
include an exhaustive list of exemptions, and the reference database, containing the classified therapeutic 
arsenal to be implemented in commercial software. We showed the strengths and limitations of INN prescribing 
perceived by Flemish general practitioners, pharmacists, medicine students and pharmacy students. An overview 
of the regulation of INN prescribing and generic substitution in different European countries was made, including 
a comparison of the exemptions related to these policies. Finally, differences in pharmacokinetic outcomes due 
to switching between medicinal products was investigated through an individual bioequivalence trial with 
gabapentin 800 mg tablets.  
This thesis can serve as a basis for European and national regulatory authorities to evaluate, optimize and 
harmonize the regulation on INN prescribing and generic substitution.  
1. MAIN FINDINGS 
Chapter 1 describes the Belgian project to prepare the implementation of INN prescribing in electronic 
prescribing and the electronic medical record. It shows that a structured approach, involving all stakeholders is 
crucial. For projects involving different stakeholders (such as regulatory authorities, innovative and generic 
pharmaceutical industry, software vendors, health care professionals and academia), it is important to take into 
account and combine all different interests. If not, this might jeopardize a successful outcome (Chapter 2). 
Transparently reporting the implementation approach can be useful for other countries as it provides important 
lessons learned.  
In Chapter 2, the results of an opinion survey with general practitioners (GPs) and pharmacists are presented. 
The general opinion was that INN prescribing can contribute to rational drug prescribing and utilization and to 
reduce pharmaceutical expenditures. However, INN prescribing should be carefully elaborated, and not solely 
be turned into a cost-containment measure. The GPs and pharmacists indicated that the policies introduced in 
spring 2012 impaired continuity of treatment and could therefore compromise patient safety. GPs also 
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mentioned a need to implement INN prescribing in their medical software (Chapter 1). This study showed that 
many issues can be avoided by first consulting the stakeholders who will be affected by the new policies  
(Chapter 1).  
The medicine students and pharmacy students in Chapter 3 confirmed the opinions of their peers (Chapter 2), 
but they also recognized the potential benefits of INN prescribing. Students wish that INN prescribing is more 
prominently, but not exclusively, taught during training. Their attitudes favor a more thorough and rational 
implementation of INN prescribing in education and in clinical practice.  
In Chapter 4, we explored the differences between European countries with regard to INN prescribing regulation 
and the related concept of generic substitution (which is not allowed in Belgium). Some countries allow both INN 
prescribing and generic substitution, but usually only one is endorsed or is even mandatory. Similarly to the 
Belgian regulation (Chapter 1), most countries selected medicinal products which are not suitable for INN 
prescribing and/or generic substitution. Although most countries exempt medicinal products referred to as 
narrow-therapeutic index drugs (NTIDs), for example antiepileptic drugs (AEDs), immunosuppressive agents, 
cardiac glycosides and thyroid hormones, these national lists of NTIDs also differ widely. This variation might be 
explained because of the lack of an official European definition and exhaustive list of NTIDs. Therefore, countries 
such as Belgium, had to rely on definitions and information from outside Europe and from national regulating 
authorities within Europe, with own definitions and already established lists of exemptions (Chapter 1).  
A potential rationale for exempting certain products from INN prescribing and/or generic substitution (Chapter 
4) was studied in Chapter 5. The results of the clinical trial showed that the brand and generic product of 800 mg 
gabapentin are bioequivalent, also on the individual subject level. This means that switching between this brand 
and generic product does not result in differences in pharmacokinetic parameters (AUC0-inf and Cmax) and that 
both products are thus interchangeable. The AED gabapentin was used as the test molecule, as AEDs are, by 
principle, frequently exempted from INN prescribing and/or generic substitution (Chapter 1 & Chapter 4). These 
results can strengthen the confidence of health professionals and patients in bioequivalence and 
interchangeability between brand and generic products. The results also provide valuable information for 
regulatory authorities occupied with elaborating the regulation on INN prescribing and/or generic substitution. 
2. IMPLICATIONS FOR PRACTICE  
To make from INN prescribing the success story it can be, there are several points that need further attention. 
Changes to the concept of INN prescribing might also be needed, both in Belgium and Europe. The points of 
attention and changes involve different aspects, such as harmonization of the regulation, guaranteeing the 
continuity of treatment, smooth implementation in electronic prescribing and in medical and pharmaceutical 
education.   
Below we discuss these points of attention and make suggestions for changes in Belgium and Europe.  
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2.1. POINTS OF ATTENTION FOR BELGIUM 
In Belgium some inconsistencies between the regulation on INN prescribing and other regulation and 
reimbursement policies need to be clarified. This is necessary to avoid confusion and reluctance of prescribers 
and to benefit from INN prescribing as an alternative, high-quality way of prescribing.  
2.1.1. INCONSISTENCIES 
Controlled drugs 
The first inconsistency is related to the Belgian law on controlled drugs [1,2] which obliges the prescriber to 
specify the total amount of product to be dispensed and write it in full (e.g. ‘thirty tablets’ instead of ’30 tablets’). 
However, the total amount of product to be dispensed is not a standard item on an INN prescription, where this 
amount is determined by combination of daily dose and duration of treatment. Writing the total amount of 
product to be dispensed in full is a precautionary measure to avoid confusion and misreading when prescriptions 
are written by hand. However, nowadays, most prescriptions are electronically written and printed, which 
decreases the chance of confusion substantially. It should be discussed by the regulatory authorities how to 
manage this inconsistency. It might be possible that the total amount of units to be dispensed is calculated and 
added automatically by the prescribing software or is added manually by the prescriber in case of a paper 
prescription. In addition, controlled drugs can also be exempted from INN prescribing, as is the case in some 
European countries (e.g. France and Spain). 
Pro re nata use 
The second inconsistency is related to pro re nata (PRN) use (if-needed use), where it is difficult to determine the 
exact amount of intakes and duration of treatment. We suggest that in this case, the prescriber indicates a 
maximum amount of units to be dispensed per day and per treatment period.  
Groups of cheapest medicinal products available 
Next are some important differences between the rules for the operationalization of INN prescribing applied by 
the Belgian medicines agency (FAGG/AFMPS), described in Chapter 1, and the rules applied by the health 
insurance institute (RIZIV/INAMI) for defining the groups of cheapest medicinal products available. Although the 
health insurance institute refers to the rules described in Chapter 1 for making an INN prescription, it applies 
different rules for dispensing an INN prescription.  
The first difference is that the groups of cheapest medicinal products available contain an additional key element, 
i.e. package size. This element had to be included in response to the policies introduced in 2012 and to define 
which products are the cheapest (based on the price per unit). The package size also links the reimbursement 
rules to INN prescribing.  
The second difference is the operationalization of the third key element, method of administration, for the 
groups of cheapest products available. The method of administration, described in Chapter 1, refers to a list of 
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23 single terms and 13 combination terms to categorize the Belgian therapeutic arsenal into groups of 
interchangeable products. Different terms are used for determining the groups of cheapest products available, 
such as ‘solid oral’, ‘solid oral, delayed action’, ‘liquids’ and ‘injections’ [3]. These different terms are not in line 
with the terms used to make a correct INN prescription. It leads to fragmentation of the groups of cheapest 
medicines, which could have been avoided, by aligning with the rules for the operationalization of INN 
prescribing.  
Thirdly, the third key element is not always referred to as ‘method of administration’ in the documents and on 
the website of the health insurance institute. It is sometimes referred to as ‘way of administration’ or 
‘method/way of administration’. This jumble of terms and definitions should be avoided in order not to further 
contribute to confusion and reluctance against INN prescribing.  
Reimbursement policies 
Finally, some inconsistencies with several reimbursement policies need to be addressed. For reimbursable 
medicinal products, the duration of treatment is limited to 92 days [4]. As a result, when the daily dose is one 
unit per day, large medicinal product packages containing more than 92 units cannot be prescribed by INN and 
are not eligible for reimbursement. This is because in a ‘once daily’ regimen, the duration of treatment would 
exceed those 92 days. However, dispensing one large package is usually cheaper than dispensing multiple smaller 
ones. Therefore, we recommend to extent the limit in duration of treatment to make it possible to prescribe and 
dispense the largest available package for products with a ‘once daily’ regimen. 
Another reimbursement policy related to INN prescribing states that the amount of units dispensed cannot 
exceed the amount of units determined on the prescription, in order to obtain reimbursement. Therefore, it 
might occur that a much smaller package need to be dispensed if there is no suitable package size available. This 
might result in an abrupt discontinuation of the treatment and in additional, but unnecessary, consultations. This 
might occur if a physician prescribes, for example, a 14-day treatment with 3 times a day 50 mg diclofenac. In 
this case, 42 tablets should be dispensed. However, on the Belgian market only packages of 30 and 50 tablets 
are available. As a result of the above described reimbursement policy, the patient should be dispensed a 
package of only 30 tablets, which implies a treatment of only 10 days. To avoid such situations, we suggest to 
determine which packages sizes can be dispensed based on specific ranges of units (e.g. 30 to 50 tablets 
prescribed means that packages up to 50 tablets can be dispensed).  
2.1.2. FIXED PACKAGE SIZES 
The above described inconsistency with the current reimbursement policies also addresses the problem related 
to the available and fixed packages sizes.  
Package sizes are mainly suitable for the recommended daily dose and duration of treatment. However, 
economical and practical aspects, with regard to the production, packaging and distribution process, are also 
taken into account by the pharmaceutical companies. As a result, available package sizes are not always in line 
with the prescribed treatment, which can lead to substantial waste of medicinal products. When patients are 
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(unnecessarily) dispensed a large package, they also have access to excessive amounts of medicinal products at 
the same time. This can lead to potential dangerous situations such as overdosing.  
Individual medication packaging 
A possible solution for INN prescribing and non-adjusted package sizes can be individual medication packaging 
(IMP). IMP is when one or multiple medicinal products for one patient are taken out of their primary package 
and rearranged in a closed individual package format for administration at a certain point of time. IMP for 
ambulatory care is in Belgium possible since December 2012 [5]. It was introduced to contribute to the role of 
the pharmacist as caregiver and is mainly used for (older) patients with polypharmacy. The aim is to detect and 
solve medication errors in order to prevent adverse drug reactions, to reduce overconsumption and to improve 
patient safety and medication adherence [6]. Currently, IMP is a developing concept as it is only advised for 
certain groups of patients and only possible for predefined (groups of) medicinal products (such as solid products 
for oral administration, e.g. tablets, capsules) [7]. However, before considering IMP, related practical and 
economical aspects should be taken into account. These aspects concern investments related to specific 
infrastructure (space, equipment, quality control, transport) and staff which are necessary for a qualitative IMP 
process [6–8]. In Belgium, pharmacies offering IMP receive a standard fee (e.g. per dispensing, per patient or per 
period) from the health insurance to compensate for the investments made [9].  
INN prescribing can be linked to IMP. This implies a step back from fixed package sizes, which are usually related 
to a specific manufacturer. However, it should be discussed whether the advantages of IMP and INN prescribing 
can outweigh the additional investments and costs. 
2.1.3. CONTINUITY OF TREATMENT 
Maintaining continuity of treatment, in particular for chronic treatment, is another point of attention for INN 
prescribing regulation. To address this, different scenarios are possible. In the first scenario, with regard to the 
obligation to dispense one of the three cheapest medicinal products with an INN prescription, an exemption can 
be introduced, for example for treatments exceeding a period of 28 days. The second scenario involves a 
quarterly or biannually update of the lists of cheapest medicinal products, instead of a monthly one.  
Frequent medication switches can result in reduced treatment persistence [10,11] and can confuse patients 
[12,13]. Confused patients are at risk for erroneous drug use, e.g. involuntary duplicate intake [14], medication 
non-adherence [15], unnecessary complications, therapeutic failure and even disability and death [16]. The 
resulting costs can override the savings made by INN prescribing and generic substitution [12]. Patient confusion 
is mainly caused by changing appearance of the switched medicinal products, e.g. changes in pill color [17–20]. 
Therefore, a third scenario involves the compulsory improvement of medicinal product packages and their 
appearance, as is also mentioned by other researchers [11,17,19–21]. We suggest a standardization of products 
packages in terms of color and labelling, with a more prominent position for the INN. For the appearance of the 
medicinal product, a standardization in terms of color, shape and taste is recommended.  
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2.1.4. ANTIEPILEPTIC DRUGS 
As described in Chapter 1, all available AEDs in Belgium are on the NO SWITCH-list. The main reason for including 
AEDs on this list was patient safety, as many of the AEDs are considered as NTIDs or very toxic molecules. No 
distinction was made between AEDs with or without NTI and therefore also AEDs such as gabapentin, lacosamide, 
lamotrigine, levetiracetam, oxcarbazepine, pregabalin, stiripentol, tiagabine, topiramate and vigabatrine were 
included. However, the results of the clinical trial presented in Chapter 5 challenge the place of AEDs without NTI 
on the NO SWITCH-list, in particular gabapentin (800 mg tablets). Besides the distinction between AEDs with and 
without NTI, also the indication for prescribing AEDs is important. There is no doubt that epilepsy is an 
unpredictable disease which causes uncertainty in patients and can have serious consequences when therapy 
fails. However, some AEDs can also be prescribed for other indications, e.g. gabapentin for the treatment of 
neuropathic pain, pregabalin for neuropathic pain and anxiety disorder and topiramate for the prophylaxis of 
migraine in adults. It can be questioned whether also a distinction based on indication should be made.  
The results of Chapter 5 also indicate that the differences in pharmacokinetic outcomes between branded and 
generic gabapentin 800 mg tablets can be neglected and are probably not the cause of a potential therapy failure 
in case of a medication switch. As described above, a possible explanation for therapy failure after switching 
between bioequivalent products can be the lack of medication adherence. However, it must be said that our 
clinical trial was performed in healthy volunteers and only used a single dose treatment.  
2.1.5. RATIONAL STOCK MANAGEMENT 
INN prescribing can contribute to a more rational stock management in the pharmacy. However, as indicated by 
pharmacists in Chapter 2, this is currently not possible as the lists of cheapest products available changes on a 
monthly basis. Therefore, the above suggested quarterly or biannual update of these lists might contribute to 
rational stock management.  
In addition, public tenders for outpatient care can be another option to improve stock management and to 
stimulate price competition for medicinal products. Tendering can be defined as a method where large volumes 
of medicinal products are bought from the manufacturer with the best offer [22]. It is frequently used in hospital 
settings. Tendering can contribute to transparency in the use of public budgets and is mostly implemented for a 
period of one year or longer [22,23].  
In addition, pharmacists mentioned that the policy of May 2012, for acute treatment with antibiotics or 
antifungal agents, can also be extended towards other groups of medicinal products, in order to contribute to 
rational stock management. However, extending this policy towards medicinal products for chronic treatment 
will implicate a major change and should be carefully considered. If the Belgian regulatory authorities are 
planning to extent this policy towards other groups of medicinal products, these groups should be carefully 
chosen, in order to assure patient safety, to prevent serious adverse drug reactions and potential extra costs. 
These extra costs can derive from additional consultations and medical tests and from the treatment of ADRs, 
due to frequent medication switch [24,25]. Some precautionary measures, such as the NO SWITCH-list and the 
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possibility for the prescriber to deviate from the obligatory switch, were already taken when introducing the 
policy, but it remains important to manage the other issues described above. In addition, data confirming the 
overall financial benefits of (automatic) switching towards the cheapest product available is currently lacking 
[26]. 
2.1.6. REASONS FOR RELUCTANCE TOWARDS INN PRESCRIBING 
The results of Chapter 2 and Chapter 5 showed that the reluctance of prescribers towards INN prescribing is 
usually not the result of a distrust in the quality of generics, which previously existed [13,19,27–30]. The possible 
explanation for the limited success of INN prescribing is twofold. Firstly, parallel to the introduction of INN 
prescribing, also the quota for prescribing cheap medicines were introduced and prescribers can be penalized if 
they do not meet their quota. Secondly, INN prescribing was never stimulated by providing a financial 
compensation for prescribers nor was it related to a minimum percentage of INN prescriptions that had to be 
prescribed. In contrast, pharmacists receive a (small) fee for each INN prescription which is dispensed. Fixing the 
imbalance for provided fees related to INN prescribing can be a progress in the right direction [31], also for 
improving the relationship and collaboration between physicians and pharmacists.  
In addition, the policies introduced in 2012 imply that only the three cheapest medical product packages are 
reimbursed. When patients wish to receive their regular medicinal product, they are obliged to pay the full price 
of the medicinal product package. This detrimental obligation and restriction of the patients’ and prescribers’ 
free choice can also contribute to the existing reluctance.  
Electronic INN prescribing 
Furthermore, as commented in our study presented in Chapter 2, making an INN prescription with prescribing 
software or documenting it correctly in the patient’s medical file is (often) not possible. Therefore, INN 
prescribing should be implemented in medical software as soon as possible and, later on, also being rolled-out 
in e-prescribing. The largest part of the preparatory work is already done, as described in Chapter 1. It should 
also be possible for the prescriber to receive detailed information on the dispensed medicinal product package. 
Additionally, to assure continuity of treatment with INN prescriptions, every pharmacist (and the GP of the 
patient) should also have access to a shared patient’s pharmaceutical file. The first private initiative to accomplish 
such a shared pharmaceutical file between pharmacies was already taken in 2014 [32]. However, sharing 
information between pharmacies and other health professionals is not possible yet [33]. Providing access to 
patient-specific information for physicians, pharmacists and also the patient is necessary to guarantee patient 
safety, but privacy and protection of personal information should also be taken into account.  
Liability 
The importance for the prescriber to receive detailed information about the dispensed medicinal product 
package is also related to liability. Prescribers can still be accountable if the dispensed medicinal product results 
in an ADR, even if a switch was performed at dispensing level and without the prescriber’s permission [13].  
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Within the framework of the recently applied reimbursement policies for INN prescribing and/or generic 
substitution, it might be appropriate to review the liability conditions for each stakeholder involved in the drug 
utilization process (e.g. the regulatory authorities, the health insurance institute, pharmaceutical industry, the 
prescriber, the pharmacist, the patient).  
2.1.7. EDUCATION 
Medicine and pharmacy students recognized the potential benefits of INN prescribing. Therefore, more focus on 
INN prescribing in education can stimulate young physicians to prescribe by INN, in order to further reduce the 
pharmaceutical expenditures. The beneficial effect of teaching INN prescribing is already proven in England, with  
83 % of all prescriptions written by INN in 2009 [34].  
However the suggestions described above are recommended from a Belgian point-of-view, they can also be 
applicable to other European countries, provided adjustments towards each country’s specific health care system 
and prescribing regulation.  
2.1.8. POTENTIAL SAVINGS 
As the last point of attention, the savings accomplished by introducing the new policies on INN prescribing in 
spring 2012 should be discussed. One year after the introduction, a saving of € 9.8 million for the health insurance 
and € 3.7 million for patients was estimated [35]. Although every saving is beneficial and can result in scarce 
resources being more efficiently used, these savings should be interpreted taking into account the annual 
pharmaceutical expenditures. These were € 2 700 million for the health insurance and € 500 million for patients 
in 2012 [36]. This means that the new introduced policies lead to a saving of only 0.36 % and 0.75 % for the health 
insurance and patients, respectively.  
2.2. POINTS OF ATTENTION FOR EUROPE 
2.2.1. INN PRESCRIBING & GENERIC SUBSTITUTION 
In Europe, INN prescribing is, at the moment, only regulated at the national level. However, the results of this 
thesis indicate that there is a need for European guidelines and regulation to harmonize the differences in 
national regulation.  
We make suggestions for topics to be addressed in these European guidelines with regard to INN prescribing. 
However, these suggestions may also be applicable for generic substitution, provided that it is allowed.  
Firstly, we suggest to establish an official definition of a NTID within Europe and an exhaustive list of active 
ingredients considered as NTID. There is a strong need for this definition and corresponding list as shown in 
Chapter 1. This need is also confirmed by the results of Chapter 4, as many countries considered different active 
ingredients as NTID when establishing their regulation on INN prescribing and/or generic substitution.  
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Secondly, because of the large differences between European countries in (groups of) medicinal products 
exempted from INN prescribing and/or generic substitution, we believe a scientific-based, European guideline 
might be useful. In this way, information can be provided on which (groups of) medicinal products are not advised 
to be prescribed by INN or to be substituted. Based on the results of Chapter 4, a European guideline might 
exempt anti-arrhythmia agents, biologicals and biosimilars, cardiac glycosides, coumarin anticoagulants, thyroid 
hormones and products used with specific aids. For immunosuppressive agents, it should be discussed whether 
these should only be exempted when indicated for the prophylaxis of graft-versus-host disease, as suggested by 
the Netherlands. Whether to exempt antiepileptic agents which are only indicated for epilepsy should also be 
discussed and in particular gabapentin, taking into account the results of Chapter 5. In addition, more clinical 
trials to establish individual bioequivalence, such as ours described in Chapter 5 and access to results of clinical 
(bioequivalence) trials performed by sponsors can provide additional information to make these decisions. This 
latter is already attributed as since 21 July 2014 sponsors are obliged to publish clinical trial summary results in 
the European Clinical Trial (EudraCT) database, managed by the European Medicines Agency [37].  
Thirdly, similar to some national regulation, we recommend that the European guideline also describes specific 
situations in which INN prescribing and/or generic substitution are not advised and includes the possibility for 
prescribers to prohibit it (e.g. for patient-specific reasons). When establishing this guideline, it might be useful 
to study, evaluate and take into account all the situations described in national regulation, in particular the 
difference made between medicines for acute and chronic treatment e.g. in Italy.  
2.2.2. UNIFORMIZATION OF MEDICATION APPEARANCE 
National standardization of medication appearance and packages might reduce patient confusion and contribute 
to medication adherence. Standardization on a European level might also be beneficial, in particular when 
medicines are imported from other (European) countries. Medication import can occur in two situations. The 
first is when certain medicinal products are not available in a country, because it has no marketing authorization 
(yet) or it is temporarily or not yet available. This is mainly applicable for hospital pharmacies. The second 
situation refers to parallel import of medicinal products. Parallel import is when medicinal products 
manufactured for a national market in a European country are imported and sold in another European country, 
mainly for commercial reasons [38–40].  
Within the framework of medication import, we believe that it can also be useful to standardize the Summary of 
Product Characteristics (SPC) and the Patient Information Leaflet (PIL) per group of interchangeable products 
and within Europe. Differences in information in SPCs and PILs of interchangeable products exist both on a 
national and European level [41,42]. These differences might also confuse patients and therefore compromise 
medication adherence.  
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2.2.3. PHARMACOVIGILANCE 
Chapter 1 described INN groups comprising interchangeable products and labelled by three key elements (the 
therapeutic moiety/INN, the strength and the method of administration). This universally applicable concept can 
also be useful in pharmacovigilance, e.g. the Periodic Safety Update Report (PSUR) synchronization list. The 
synchronization list is the result of a work sharing and synchronization project under the auspices of the Heads 
of Medicines Agencies (HMA) and the European Risk Management Strategy Facilitation Group (ERMS FG) [43]. 
Currently, this list is only based on one element: the INN [44]. Adding ‘strength’ and ‘method of administration’ 
to the INN and assuring accurate identification and codification procedures can provide more detailed 
information and more in-depth review of the benefit-risk balance of medicinal products.  
2.3. INN PRESCRIBING IN HOSPITAL SETTING 
The regulation on INN prescribing and generic substitution described in this thesis is mainly, if not only, 
established for outpatient care. However, INN prescribing and generic substitution are concepts which can be 
and are used in a hospital setting. The regulation of these concepts should distinguish between (1) the medicinal 
products exclusively used in hospitals and (2) medicinal products available in the hospital and used in both 
outpatient and inpatient care. The implementation and operationalization will depend on whether electronic 
prescribing or paper prescribing is used and whether therapeutic substitution is possible (see further). The 
regulation will also be influenced by which medicinal products are available in the hospital, sometimes 
determined by tendering, and whether medicines formularies are applied (which mainly include brand products). 
Medication management is an important part of seamless care, which is the continuity of care between different 
healthcare settings [45,46]. INN prescribing can result in budget savings when applied at discharge as the 
cheapest medical product will be dispensed for newly prescribed medication. It can also contribute to 
maintaining continuity of treatment as the patient’s regular home medication will be dispensed. Provided some 
suggestions to assure continuity of treatment mentioned above are taken into account, INN prescribing in 
hospital setting (at discharge) can contribute to seamless care.  
2.4. THERAPEUTIC SUBSTITUTION 
Therapeutic substitution can be defined as switching the prescribed medicinal product towards another product 
with assumed equivalent therapeutic effect. The other product may be within the same therapeutic class (e.g. 
switch from omeprazole towards pantoprazole) or can be from another class (e.g. switch from a proton pump 
inhibitor (PPI) towards a H2-antagonist) [13].  
Therapeutic substitution occurs often automatically when patients are admitted to hospital, where formularies 
are applied for practical reasons (e.g. stock management, availability of space, budgets). Automatic therapeutic 
substitution should be possible between medicinal products from the same therapeutic class where no 
significant difference could be detected. It mainly occurs for medicinal products such as H2-antagonists, PPIs, 
statins, ACE-inhibitors, insulins and laxatives [47,48]. Therapeutic substitution can contribute to cost savings in 
both in- and outpatient care, but only when applied in a rational way and taking into account a patient centered 
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approach (e.g. seamless care). However, whether therapeutic substitution by non-clinicians (e.g. at the public 
pharmacy) should be possible has to be investigated and discussed carefully.   
2.5. BIOLOGICALS & BIOSIMILARS 
A biological medicinal product (also referred to as a ‘biological’) is defined as a product which contains a biological 
substance. This substance is produced by or extracted from a biological source. Biological substances and their 
production process are subject to physico-chemical and biological tests, in order to control their characteristics 
and to determine their quality. Examples of biologicals are recombinant proteins, monoclonal antibodies, 
medicinal products derived from human blood and plasma and immunological medicinal products [49,50].  
A similar biological medicinal product (also referred to as a ‘biosimilar’) is defined as a product similar to its 
reference biological product. The active substance of a biosimilar is a known biological active substance and is 
similar to the reference medicinal product. Biologicals and biosimilars are in general indicated for the same 
conditions and are expected to have the same safety and efficacy profile [49,50].  
It is clear that due to their biological origin, biologicals and biosimilars are not ordinary medicines, containing 
reproducible chemical compounds. The current scientific and technological innovations result in more biologicals 
and biosimilars being introduced, which makes the assignment of INNs and establishment of bioequivalence and 
interchangeability more complex and challenging [51]. This latter and whether biologicals and biosimilars should 
have the same INN is being extensively discussed by different stakeholders, including proponents and opponents 
[52–57]. Therefore, this issue is investigated and anticipated by the WHO Program on INNs, in order to guarantee 
transparency, effective data collection and a pharmacovigilance system that prioritizes patient safety [51].  
In anticipation of decisions on the nomenclature and appropriate methods for the establishment of 
interchangeability, biologicals and biosimilars are exempted from INN prescribing and/or generic substitution in 
some European countries (e.g. Belgium, Finland, Lithuania and Spain).  
3. IMPLICATIONS FOR FURTHER RESEARCH 
The INN nomenclature was established in a logical way in order to contribute to rational drug naming, prescribing 
and dispensing. The INNs have distinct sound and spelling and pharmacologically related active ingredients can 
be recognized by their common suffix. It might be useful to make scientists, including health professionals, more 
aware of the strengths of the INN nomenclature and the advantages of using the INN for prescribing. 
In Chapter 2 and 3, the attitudes of (future) physicians and pharmacists towards INN prescribing one year after 
the introduction of the austerity measures in Belgium were investigated. It would be interesting to explore the 
current attitudes of the GPs and pharmacists who participated in 2013 and investigate whether and how their 
attitudes have changed. For the medicine and pharmacy students, a follow-up study should explore whether and 
how their attitudes have changed after some years of practical experience. For both future studies a 
questionnaire or a qualitative approach with e.g. semi-structured interviews or focus groups can be used.  
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Chapter 4 compares the exemptions related to INN prescribing and/or generic substitution between 16 European 
countries. The comparison of the percentage of INN prescriptions and/or prescriptions substituted per country 
could add valuable information to this research. However, this will be a serious endeavor as data on how 
medicinal products are prescribed (by brand name, by branded generic name or by INN) and which products are 
dispensed (brand product or generic product) need to be collected. The data should be compared within the 
framework of each country’s prescribing and reimbursement regulation. In addition, data on generic drug 
utilization and the cost savings through INN prescribing and/or generic substitution might be compared for all 
European countries.  
Furthermore, the evolution of policies involving INN prescribing and/or generic substitution within each country 
can be investigated in future research. It should be interpreted together with the effect of the policy changes on 
the percentages of INN prescriptions and/or substitution and the achieved cost savings. This can provide an 
insight in important lessons learned from other countries.  
4. STRENGTHS & LIMITATIONS 
This thesis was the first to investigate thoroughly different aspects of INN prescribing in Belgium and Europe 
from a scientific point of view.  
It provides detailed information on how Belgium prepared INN prescribing for the implementation in electronic 
prescribing, which can serve as a basis for other countries planning to operationalize electronic INN prescribing. 
This thesis addressed the shortcomings of the Belgian regulation of INN prescribing and provides suggestions for 
improvements. It also contains an overview of important differences in the regulation of INN prescribing for 16 
European countries. It shows the need for a European guideline on this topic in order to harmonize the 
differences between countries and suggestions for topics to be addressed in this guideline are given.  
During this research, a clinical trial in 30 healthy volunteers was performed to investigate interchangeability 
between a brand and generic product and thus the potential pharmacokinetic rationale for exempting certain 
products from INN prescribing and/or generic substitution. The results of this study can contribute to the 
confidence of health professionals and patients in generics and interchangeability, provided correct medication 
use and adherence. This study also provides detailed information for researchers interested in performing 
individual bioequivalence studies. Although different (groups of) medicinal products are exempted, we only 
investigated interchangeability for gabapentin, an AED which is frequently exempted from INN prescribing 
and/or generic substitution, despite it is not considered as an NTID.   
The aim was to present an internationally applicable research. However, in certain aspects this thesis focusses 
on Flanders and Belgium. Therefore, some outcomes might be perceived as reflecting a regional and national 
perspective. Despite this, large parts of this thesis can be applicable and useful for other European countries, 
provided correct interpretations and adaptions.  
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In this thesis, we focused on INN prescribing (and generic substitution) in outpatient care. However, it would also 
be interesting to investigate whether INN prescribing is applied in hospitals, how it is regulated and whether 
there are differences between different hospitals and across European countries. In addition, an overview of how 
regulatory authorities and hospitals across Europe try to accomplish seamless care could be useful in order to 
share good ideas and pitfalls.  
For the 16 European countries in this thesis we did not investigate pricing and reimbursement policies, nor did 
we investigate the percentages of generic drug utilization. A full pharmaco-economic appraisal of prescribing 
regulation, and in particular INN prescribing regulation is still to be performed.   
Finally, the issues related to assigning INNs and establishing interchangeability of biologicals and biosimilars are 
currently being extensively discussed in different media. As biologicals and biosimilars cannot be treated as 
ordinary medicines, they were beyond the scope of this thesis and therefore not further discussed.  
5. FINAL VIEW 
The concept of INN prescribing comprises many potential benefits, as described throughout this thesis. However, 
we also addressed a number of attention items related to INN prescribing. These need to be addressed at 
national and European level in order to make INN prescribing an attractive, high quality way of prescribing with 
advantages for physicians, pharmacists, patients and the health insurance.  
To turn INN prescribing into the preferred method for rational drug prescribing, the different interests from all 
stakeholders need to be aligned. Implementation of INN prescribing should foster rational prescribing, decrease 
pharmaceutical expenditures, without compromising patient safety and without restraining innovation in 
pharmaceutical industry, and promote and protect the health of all European citizens.  
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